	Sanger technology	454 FLX technology	Sanger + 454 FLX

Total number of reads	14,120	789,105	-

Average length of read (bases)	780	218	-

Total number of reads in the assembly	12,032	466,737	478,769

Total number of contigs	2,120	22,203	18,690

Total number of singlets	4,775	25,604	-

Number of unique sequences	6,895	47,807	-

Average/Largest contig size	995/3,560	1132/4,762	1180/4,762


		B2	HTK	Euro Collins

Osmolality (mosm/kg)		323	310	406

Ions (mmol/l)	Na+	22	15	10

	K+	150	9	115

	Mg++	10	4

	Cl-	10	50	15

	SO4-	85

Buffers (mmol/l)	PO4---	6

	HPO4--			43

	H2PO4-			15

	HCO3-			10

	Histidin		198

Osmotics (mmol/l)	Glucose			198

	Mannitol		30

	Saccharin	40

Colloids (mmol/l)	PEG	25


Primer name	Oligonucleotide	Product length	Product name

crdPG-1	GTACTCGAGATTGTCGGCAGTCCAG	607	crdP

crdPG-2	AGCTCCTCGCCCTTGCTCACCATGAAATCAACTCCTCTGT

GFP-1	ACAGAGGAGTTGATTTCATGGTGAGCAAGGGCGAGGAGCT	746	GFP

GFP-2	CGCGGATCCTTACTTGTACAGCTCGTCCATG		crdP

crdP-1	TCACCAACACCAACTCTGGA

crdP-2	CATGAAATCAACTCCTCTGT	607	crdP

crdP142-1	ATCGTCAGATGCCTATTTGT	537	crdP

crdP108-1	AAATTAGTTAATGCAAT	503	crdP

crdP98-1	TTAATGCAATTTTTACTATGTT	493	crdP

crdP53-1	CCATTTCAATACTGCGGGAGG	448	crdP

crdP13-1	AGGAGTTGATTTCATGCTGTT	408	crdP

crdP1-1	ATGCTGTTCCGCAATAAG	395	crdA

crdA395-2	TCGGTCCGCAGCAGCAAAG

q-crdA-1	CAAGGCATAAGCGAAGACATC	227	crdA

q-crdA-2	CTCCGTGTTTCAAGTGTGGTC

q-crdS-1	AACCTGACGATTGCGATTGGG	179	crdS

q-crdS-2	GTGTAGCACCAGAGCGTTTCG

q-crdC-1	GTTCGGTCAGGATGCTCAAC	248	crdC

q-crdC-2	GCCAAAGTTCGGAATCAATG

crdR-1	GCCAGATCTATGACCGAGAATAAGAAAAAGCCT	437	crdR

crdR-2	TTGAGCTCTTACTCGGCGTCGCCTTCG

NcrdR-1	ACACTCGAGATACACCCGGTCCCTACCAGCATT		crdR

NcrdR-2	TTTGAGCTCCTTGTCCTTCTTCAGAAGCGTGT	1302	crdR

q-crdR-1	TCGGAATGAGCCAGGAGAAGC	238	crdR

q-crdR-2	TCAGCCGAGGACAGAAAGTCG

crdRup-1	TCTGAGCTCTTCGGCGTTTCGGAATGGTTG	2533	CrdR

crdRdown-2	CAACACAAGCTTAACCGTCACCTGGCTCTTGGCA

crdRcheckGm-2	TTGGGCATACGGGAAGAAGT	558	Gm

crdRcheckGm-1	CGGCTGATGTTGGGAGTAGG	577

Rep-Kan-1	ACGCGTCGACCTTGCCAGCCCGTGGATAT	3266	Km

Rep-Kan-2	ACGCGTCGACTCTGTGATGGCTTCCATGTC

Gm-1	ATAGTTGTCGAGATATTCACTAGTCGTCAGGTGGCACTTTTCG	1302	Gm

Gm-2	CGCGGATCCGCTCTGCTGAAGCCAGTTAC

celAP1	ACCCGGTCTATCCCATGA

celAP-2	CATCCAGAAACTTTCCGT	441	celAP

relAP-1	CCAGATTTCTCAAGGGTC

RelAP-2	CATCATGCGATATTCCACA	443	relAP

crdRP-1	GCGGCGATCCTAAATGTGAC

crdRP-2	CATGCGGTCCTGACACTCG	466	crdRP

crdSP-1	TCGGTCGGCACATGGGTCAAT

crdSP-2	CATCGCCCTAACCTCGCAGT	446	crdSP

Primer name	Oligonucleotide	Product length	Product name

crdP-2	CATGAAATCAACTCCTCTGT	607	crdP

crdP142-1	ATCGTCAGATGCCTATTTGT	537	crdP

crdP108-1	AAATTAGTTAATGCAAT	503	crdP

crdP98-1	TTAATGCAATTTTTACTATGTT	493	crdP

crdP53-1	CCATTTCAATACTGCGGGAGG	448	crdP

crdP13-1	AGGAGTTGATTTCATGCTGTT	408	crdP

crdP1-1	ATGCTGTTCCGCAATAAG	395	crdA

crdA395-2	TCGGTCCGCAGCAGCAAAG

q-crdA-1	CAAGGCATAAGCGAAGACATC	227	crdA

q-crdA-2	CTCCGTGTTTCAAGTGTGGTC

q-crdS-1	AACCTGACGATTGCGATTGGG	179	crdS

q-crdS-2	GTGTAGCACCAGAGCGTTTCG

q-crdC-1	GTTCGGTCAGGATGCTCAAC	248	crdC

q-crdC-2	GCCAAAGTTCGGAATCAATG

crdR-1	GCCAGATCTATGACCGAGAATAAGAAAAAGCCT	437	crdR

crdR-2	TTGAGCTCTTACTCGGCGTCGCCTTCG

NcrdR-1	ACACTCGAGATACACCCGGTCCCTACCAGCATT		crdR

NcrdR-2	TTTGAGCTCCTTGTCCTTCTTCAGAAGCGTGT	1302	crdR

q-crdR-1	TCGGAATGAGCCAGGAGAAGC	238	crdR

q-crdR-2	TCAGCCGAGGACAGAAAGTCG

crdRup-1	TCTGAGCTCTTCGGCGTTTCGGAATGGTTG	2533	CrdR

crdRdown-2	CAACACAAGCTTAACCGTCACCTGGCTCTTGGCA

crdRcheckGm-2	TTGGGCATACGGGAAGAAGT	558	Gm

crdRcheckGm-1	CGGCTGATGTTGGGAGTAGG	577

Rep-Kan-1	ACGCGTCGACCTTGCCAGCCCGTGGATAT	3266	Km

Rep-Kan-2	ACGCGTCGACTCTGTGATGGCTTCCATGTC

Gm-1	ATAGTTGTCGAGATATTCACTAGTCGTCAGGTGGCACTTTTCG	1302	Gm

Gm-2	CGCGGATCCGCTCTGCTGAAGCCAGTTAC

celAP1	ACCCGGTCTATCCCATGA

celAP-2	CATCCAGAAACTTTCCGT	441	celAP

relAP-1	CCAGATTTCTCAAGGGTC

RelAP-2	CATCATGCGATATTCCACA	443	relAP

crdRP-1	GCGGCGATCCTAAATGTGAC

crdRP-2	CATGCGGTCCTGACACTCG	466	crdRP

crdSP-1	TCGGTCGGCACATGGGTCAAT

crdSP-2	CATCGCCCTAACCTCGCAGT	446	crdSP


lectin	time (dpi/dpe)a	mucusb	SMCc	MNCd

UEAI	0	+/-	-	++

	14	+/-	+/-	++

	21	+	+	++

	60	+	+	++


HRV Index	Sitting Variable	Crude Model (N = 126)	Primary Adjusted Model (N = 126)

B	95%CI Low	High	p	B

IBI (ms)	Occupational sitting	−17.00	−35.80	1.81	0.08	−24.24

	Leisure-time sitting	6.80	−7.97	21.57	0.36	0.41

RMSSD (ms)	Occupational sitting	−3.26	0.06	−6.66	0.14	−4.96

	Leisure-time sitting	0.16	0.91	−2.51	2.83	1.83

SDNN (ms)	Occupational sitting	−3.03	−5.87	−0.20	0.04	−5.07

	Leisure-time sitting	0.46	−1.77	2.69	0.68	1.10

ln VLF	Occupational sitting	−0.10	−0.20	0.01	0.06	−0.19

	Leisure-time sitting	0.03	−0.05	0.11	0.50	0.00

ln LF	Occupational sitting	−0.13	−0.25	−0.01	0.03	−0.18

	Leisure-time sitting	0.05	−0.04	0.14	0.30	0.07

ln HF	Occupational sitting	−0.12	−0.26	0.03	0.12	−0.12

	Leisure-time sitting	0.00	−0.12	0.11	0.95	0.08

ln LF/HF	Occupational sitting	−0.01	−0.12	0.10	0.91	−0.03

	Leisure-time sitting	0.06	−0.03	0.14	0.19	−0.01


	24‐hr mean Tb (°C)	24‐hr maximum Tb (°C)

No f	Fee	No fe	Feed


Preparation	Average finish line width (mm)

CCC 46	0.5

MCC 24	(0.5 + 1.2)/2 = 0.85

MCC 46	(0.5 + 0.8)/2 = 0.65

ACC 21	1

Preparation

CCC 46

MCC 24

MCC 46

ACC 21


Peptide	COX-1	COX-2

be	ir	hb	be	ir	hb

GMD	−1.20	23	1	−39.87	21	3

GHE	−0.56	25	0	−42.15	26	5

YYV	—	—	—	—	—	—

Peptide	COX-1

be	ir

GMD	−1.20	23

GHE	−0.56	25

YYV	—	—


Antibody	Growth inhibition (%) over the period of cultivation

1 mg/ml IgG

	Day 1	Day 2	Day 3	Day 4


TB CX-test	AFB staining (+)	AFB staining (−)	Totals

TB CX-test(+)	12	1*	13

TB CX-test(−)	0	83	83

Totals	12	84	96


Variables	Mean	95% CI of the mean	Statistics (P values)

IBS symptom score	1.57	0.10; 3.05	P = 0.04

Bacteroides	−0.01	−0.11; 0.08	ns (P = 0.77)

Faecalibacterium	−0.03	−0.18; 0.12	ns (P = 0.63)

Lachnospiraceae	0.05	−0.03; 0.13	ns (P = 0.18)

“Common” Simpson's D	−0.04	−0.15; 0.08	ns (P = 0.50)


Reason	No. of patients	% patients

Presence of any types of primary disease progression (n = 26)

Enlargement of tumor	14	47

Elevation of tumor marker	7	23

Carcinomatous pain	5	17

Obstructive jaundice	5	17

Duodenal hemorrhage	2	7

Absence of disease progression (n = 4)

Interstitial pneumonia	4	13

Reason	No. of patients

Presence of any types of primary disease progression (n = 26)

Enlargement of tumor	14

Elevation of tumor marker	7

Carcinomatous pain	5

Obstructive jaundice	5

Duodenal hemorrhage	2

Absence of disease progression (n = 4)

Interstitial pneumonia	4

% patients

Presence of any types of primary disease progression (n = 26)

47

23

17

17

7

Absence of disease progression (n = 4)

13


Antibodies	Manufacturer	Source	Reactivity	Dilution

CD34	Sigma	Mouse	Rat	1:100

5-HT	Immunostar	Rabbit	Rat	1:20,000

GFAP	Millipore	Rabbit	Rat	1:50

APC	Calbiochem	Mouse	Rat	1:200

NeuN	Immunostar	Rabbit	Rat	1:500

Manufacturer	Source	Reactivity	Dilution

Sigma	Mouse	Rat	1:100

Immunostar	Rabbit	Rat	1:20,000

Millipore	Rabbit	Rat	1:50

Calbiochem	Mouse	Rat	1:200

Immunostar	Rabbit	Rat	1:500


sTNF/TNFR1 signaling

sTNF is necessary for the induction of autoimmune diseases [160]

Association of TNF and TNFR1 polymorphisms with PD risk [14, 163]

Association of TNFR1 polymorphism with MS risk [164]

TNFR1 promotes neurodegeneration in retinal ischemia [165]

TNFR1 mediates development of pain-induced depressive behavior [166]

TNFR1 is essential for the development of MOG35–55 induced EAE [167–169]

Inhibition of TNFR1 signaling strongly ameliorates EAE development [169]

Blocking of sTNF improves functional outcome in EAE [170, 171]

Blocking sTNF attenuates neurodegeneration in AD and PD models [172–174]

TNFR1 mediates direct apoptosis of neurons via caspase 8 [175]

memTNF/TNFR2 signaling

TNFR2−/− mice show exacerbated neurodegeneration in EAE model [167–169]

TNFR2−/− mice show exacerbated neurodegeneration in retinal ischemia [165]

TNFR2 promotes OPC proliferation and remyelination [176]

TNFR2 protects neurons against glutamate-induced excitotoxicity [142, 143]

memTNF dependent activation of NFkB is neuroprotective in EAE [171]

TNFR2 rescues neurons from oxidative stress-induced cell death [144]

TNFR2 promotes oligodendrocyte maturation [177]

TNFR2 promotes oligodendrocyte proliferation and maturation [178]

TNFR2 protects OPCs against oxidative stress [179]


Structure	Damage Scale	Stiffness Adjustment	Flatfoot Stiffness (N/mm)

Superomedial spring	Stage IV	−7/8th	39

Inferomedial spring	Stage II	−3/8th	94

Talocalcaneal interosseus	Stage I	−1/8th	236

Plantar fascia	Stage I	−1/8th	175

Plantar metatarsocuneiform	Stage 0	None	90

Plantar naviculocuneiform	Stage 0	None	180

Long and short plantar	Stage 0	None	240

Deep deltoid	Stage 0	None	200

Anterior superficial deltoid	Stage I	−1/8th	70

Posterior superficial deltoid	Stage 0	None	117


Usage	AAindex ID	Physicochemical properties

100%	MEEJ800102	Retention coefficient in HPLC, pH2.1

91%	WOLS870102	Principal property value z2

87%	CASG920101	Hydrophobicity scale from native proteins

84%	NAKH900110	Normalized composition of membrane proteins

81%	FASG760105	pK-C

79%	FAUJ880105	STERIMOL minimum width of the side chain

76%	CHAM830107	A parameter of charge transfer capability

61%	QIAN880127	Weights for coil at the window position of -6

59%	RACS820108	Average relative fractional occurrence in AR (i-1)

58%	DIGM050101	Hydrostatic pressure asymmetry index, PAI

56%	TANS770109	Normalized frequency of coil

Usage	AAindex ID	Physicochemical properties

56%	TANS770109	Normalized frequency of coil


Treatment groups	Continuous exposure profile	Cross-over exposure profile

CC	TT	CT	TC

CC		42	53	42

TT	42		36	31

CT	53	36		39

TC	42	31	39

Treatment groups	Continuous exposure profile

CC	TT

CC		42

TT	42

CT	53	36

TC	42	31

Cross-over exposure profile

CT	TC

53	42

36	31

	39

39


XXY ID	Sequence (XX_Y)	N Species	freq (%)	N changes*

1	AAaTGAAGAAAAcGAAGA_ATGAAGA	2	2.11	2

2	AAaTGAAGAAAATGAAGA_ATGAAGA	27	28.42	1

3	AAaTGAAGAAAATGAAGA_ATGAgGA	2	2.11	2

4	AAaTGAAGAcAATGAAGA_ATGAAGA	3	3.16	2

5	AAaTGAgGAAAATGAAGA_ATGAAGA	1	1.05	2

6	AACaGAAGAAAAcGAAGA_ATGAAGA	2	2.11	2

7	AACcGAAGAAAAcGAAGA_ATGAAGA	1	1.05	2

8	AACTGAAGAAAAcGAAGA_ATGAAGA	11	11.58	1

9	AACTGAAGAAAATGAAGA_AcGAAGA	1	1.05	1

10	AACTGAAGAAAATGAAGA_ATGAAGA	40	42.11	0

11	AACTGAAGAcAATGAAGA_ATGAAGA	3	3.16	1

12	cAgTGAAGAAAATGAAGA_ATGAAGA	1	1.05	2

13	cAgTGAAGAtAAcGAAGA_ATGAAGA	1	1.05	4

XXY ID	Sequence (XX_Y)	N Species	freq (%)	N changes*

10	AACTGAAGAAAATGAAGA_ATGAAGA	40	42.11	0

11	AACTGAAGAcAATGAAGA_ATGAAGA	3	3.16	1

12	cAgTGAAGAAAATGAAGA_ATGAAGA	1	1.05	2

13	cAgTGAAGAtAAcGAAGA_ATGAAGA	1	1.05	4


Participants	Nationality	Sex	Age category	Migratory status	Health complaints	Received treatments while undocumented migrant in Denmark

P01	Bangladeshi	Male	31-40	Failed asylum seeker	Dental problems, mental health problems	None

P02	Bangladeshi	Male	31-40	Failed asylum seeker	Superficial wounds after assault, asthma	Prescription for medication fromgeneral practitioner

P03	Bangladeshi	Male	21-30	Failed asylum seeker	Psoriasis, mental health problems	Treatment for psoriasis throughinformal networks of healthcare professionals and at a hospitaldermatology department

P04	Bangladeshi	Male	41-50	Failed asylum seeker	Leg fracture, mental health problems, cancer suspicion	Treatment for a leg fracture at hospital ER, check-up athospital oncology department

P05	Indian	Male	41-50	Failed asylum seeker	Diabetes, high blood pressure, heart disease, mental health problems	Treatment for depressionthrough informal networks ofhealthcare professionals. Medical supplies throughpersonal networks

P06	Indian	Male	31-40	Overstayer	Dental problems, ulcer, sprained foot,mental health problems	Treatment for a sprained foot at hospital ER

P07	Nepali	Male	21-30	Overstayer	None	None

P08	Nepali	Male	31-40	Overstayer	Dental problems, mental health problems	None

P09	Nepali	Male	21-30	Overstayer	Sprained hand, skin allergy	None

P10	Nepali	Male	21-30	Overstayer	Mental health problems	None

Participants	Nationality	Sex	Age category	Migratory status	Health complaints	Received treatments while undocumented migrant in Denmark

P07	Nepali	Male	21-30	Overstayer	None	None

P08	Nepali	Male	31-40	Overstayer	Dental problems, mental health problems	None

P09	Nepali	Male	21-30	Overstayer	Sprained hand, skin allergy	None

P10	Nepali	Male	21-30	Overstayer	Mental health problems	None


	Linear model	Ordered probit model

Men 15-44

Gap in VAS	0.196	0.186

Prevalence effect	-0.082	-0.102

Severity effect	0.239	0.030

Interaction	0.038	-0.012

Women 65-74

Difference	-0.902	-0.664

Prevalence effect	-0.575	-0.699

Severity effect	0.305	0.372

Interaction	-0.632	-0.646

Women 75 & more

Difference	-1.205	-1.182

Prevalence effect	-1.117	-1.189

Severity effect	-0.839	-0.088

Interaction	-0.049	-0.905


Study	Criteria used for prophylaxis	Antifungal used for prophylaxis	Invasive candidiasis	Commentary

Positive prophylactic studies

*Slotman et al.1987 [77]	Abdominal surgery+ ≥ 3 risk factors	Ketoconazole 200 mg/d POPlacebo	0/27 (0%)5/30 (17%)†	Costs: $4,800 vs. $10,000†LOS: 6.0 vs. 12.5 days†

*Savino et al.1992 [78]	Surgical patients+ hypermetabolism	Nystatin/norfloxacin POPlacebo	6/25 (24%)13/21 (62%)‡	NI per patient:0.9 vs. 2.0†

Desai et al.1992 [79]	Severely burned patients	Nystatin/polymyxin SDDNo prophylaxis	34/1042 (3.3%)0/1439 (0%)†	Superficial infections:59 (21%) vs. 22 (10%)†

Eggimann et al.1999 [39] *	Abdominal surgery+ tertiary peritonitis	Fluconazole 400 mg/d IVPlacebo	1/23 (9%)7/20 (35%)‡	Candida peritonitis1 (4%) vs. 7 (35%)†

Pelz et al.2001 [43] *	Surgical patients+ LOS > 3 days	Fluconazole 400 mg/d POPlacebo	11/130 (8%)20/130 (15%)†	> 75% colonized at randomization

Garbino et al.2002 [42] *	Mechanically ventilated > 96 h	Fluconazole 100 mg PO + SDDPlacebo + SDD	4/103 (4%)10/101 (10%)‡	Candidemia: 9 vs. 1(RR 0.1; CI 0.02-0.74)†

Jacobs et al.2003 [80] *	ICU+ septic shock	Fluconazole 200 mg IV/dPlacebo	0/32 (0%)1/39 (3%)‡	Mortality significantly reduced in peritonitis

He et al.2003 [81]	Severe acute pancreatitis	Fluconazole 100 mg IV/dPlacebo	2/22 (9%)†7/23 (30%)†	Mortality 2/2 (100%)Mortality 3/7 (43%)

Negative prophylactic studies

Savino et al.1994 [78]	Surgical patients+ LOS > 2 days	Nystatin 2 × 106 4 ×/d POKetoconazole 200 mg/d POClotrimazole 10 mg 3 ×/d PONo prophylaxis	5/75 (7%)1/65 (2%)‡1/80 (1%)‡2/72 (3%)‡

Ables et al.2000 [82]*	Surgical patients+ LOS > 2 days + other risk factors	Fluconazole 3 mg/kg 3 ×/wPlacebo	8/60 (13%)11/59 (19%)‡

Sandven et al.2002 [40]*	Surgery for peritonitis	Fluconazole 400 mg/d IVPlacebo	--	Mortality rates NS4/53 (8%) vs. 8/56 (14%)

Schuster et al.2008 [83]*	ICU ≥ 4 d+ Fever > 4 d under broad-spectrum antibiotics+ APACHE II ≥ 16	Fluconazole 400 mg/d IVPlacebo	6/122 (5%)11/127 (9%)‡


Ptosis	Group A	Group B

Excellent	89% (57)	83.9% (52)

Good	9.4% (6)	9.7% (6)

Fair	1.6% (1)	6.4% (4)

Poor

Very poor

p value	0.440

Ptosis	Group A	Group B

oor

Very poor

p value	0.440


NHANES 2001–2010a	Sample size	Unweighted percent, %

All	9,568	100.0

Sex

Male	4,690	49.0

Female	4,878	51.0

Age (years)

16–19	938	9.80

20–59	7,245	75.7

≥ 60	1,385	14.5

Race/ethnicity

Non-Hispanic white	4,280	44.7

Non-Hispanic black	1,802	18.8

Mexican American	2,264	23.7

Other	1,222	12.8

Ratio of family income to poverty (PIR)

PIR < 1.0	1,669	17.5

1.0 ≤ PIR < 2.0	1,886	19.7

2.0 ≤ PIR < 3.0	1,410	14.7

PIR ≥ 3.0	4,603	48.1

Education

Below high school	1,689	17.6

High school/ general educational development 	1,718	18.0

Some college or associate’s degree	2,592	27.1

College graduate or higher	2,626	27.4

Not reported	943	9.90

aThe combined data set was from five consecutive survey cycles: 2001–2002, 2003–2004, 2005–2006, 2007–2008 and 2009–2010.

NHANES 2001–2010a	Sample size	Unweighted percent, %

Non-Hispanic white	4,280	44.7

Non-Hispanic black	1,802	18.8

Mexican American	2,264	23.7

Other	1,222	12.8

Ratio of family income to poverty (PIR)

PIR < 1.0	1,669	17.5

1.0 ≤ PIR < 2.0	1,886	19.7

2.0 ≤ PIR < 3.0	1,410	14.7

PIR ≥ 3.0	4,603	48.1

Education

Below high school	1,689	17.6

High school/ general educational development	1,718	18.0

Some college or associate’s degree	2,592	27.1

College graduate or higher	2,626	27.4

Not reported	943	9.90

aThe combined data set was from five consecutive survey cycles: 2001–2002, 2003–2004, 2005–2006, 2007–2008 and 2009–2010.


Gene	Forward (5′-3′)	Reverse (5′-3′)

Egr1	AACAACCCTACGAGCACCTG	AAAGGGGTTCAGGCCACAAA

Fgf2	GCGACCCACACGTCAAACTA	CCGTGACCGGTAAGTGTTGTA

Fgf7	TGTGGCAATCAAAGGGGTGG	AAGGCCACGAACATTTCCCC

Jak2	AGTGTGCTACAGTGCTGGTC	TTCCTTGTTGCCAGATCCCG

Mmp9	GCCGGGAACGTATCTGGAAA	GGTTGTGGAAACTCACACGC

Notch2	AACTGCACCTCCTCACTTCG	CTCCTCGTTGTTGCATCCCT

Vim	CATGCGGCTGCGAGAAAAAT	GGTCAAGACGTGCCAGAGAA

Zeb2	AAAGCAGTTCCCTTCTGCGA	AGGAGCCCGAGTGTGAAAAG

Hif1α	CTCATCCAAGGAGCCTTAACCT	TAACGTTCCAATTCCTGCTGC

Lox	AGGGCGGATGTCAGAGACTA	CATCCAGCAGGTCGTAGTGG

Cdh1	CCACCAGATGACGATACCCG	GAATCACTTCCGGTCTGGCA

Gene	Forward (5′-3′)	Reverse (5′-3′)

Eg	AACAACCCTACGAGCAC	AAAGGGGTTCAGGCCAC

r1	CTG	AAA

Fgf2	GCGACCCACACGTCAAACTA	CCGTGACCGGTAAGTGTTGTA

Fgf7	TGTGGCAATCAAAGGGGTGG	AAGGCCACGAACATTTCCCC

Jak2	AGTGTGCTACAGTGCTGGTC	TTCCTTGTTGCCAGATCCCG

Mmp9	GCCGGGAACGTATCTGGAAA	GGTTGTGGAAACTCACACGC

Notch2	AACTGCACCTCCTCACTTCG	CTCCTCGTTGTTGCATCCCT

Vim	CATGCGGCTGCGAGAAAAAT	GGTCAAGACGTGCCAGAGAA

Zeb2	AAAGCAGTTCCCTTCTGCGA	AGGAGCCCGAGTGTGAAAAG

Hif1α	CTCATCCAAGGAGCCTTAACCT	TAACGTTCCAATTCCTGCTGC

Lox	AGGGCGGATGTCAGAGACTA	CATCCAGCAGGTCGTAGTGG

Cdh1	CCACCAGATGACGATACCCG	GAATCACTTCCGGTCTGGCA


Category	Data Elements

Vascular Access	Dialysis catheter position

Dialysis catheter type (acute or tunneled)

Dialysis catheter manufacturer

Dialysis catheter size

Any need for catheter manipulation (e.g. repositioning, replacement)

CRRT Circuit	Any circuit interruptions/replacements and reasons

Priming solution (new circuits)

CRRT-Related Anticoagulation	Anticoagulation type (heparin, citrate, none, other)

Anticoagulation dose

Anticoagulation metrics

CRRT Fluids	Type of solution

Modality (dialysate, pre- and/or post-replacement) and rate

Solution additives

CRRT Dose	Prescribed effluent dose

Machine Data Card	Delivered effluent dose

Type, number and duration of machine alarms and interruptions

Filter life

Category

Vascular Access

CRRT Circuit

CRRT-Related Anticoagulation

CRRT Fluids

CRRT Dose

Machine Data Card

Data Elements

Dialysis catheter position

Dialysis catheter type (acute or tunneled)

Dialysis catheter manufacturer

Dialysis catheter size

Any need for catheter manipulation (e.g. repositioning, replacement)

Any circuit interruptions/replacements and reasons

Priming solution (new circuits)

Anticoagulation type (heparin, citrate, none, other)

Anticoagulation dose

Anticoagulation metrics

Type of solution

Modality (dialysate, pre- and/or post-replacement) and rate

Solution additives

Prescribed effluent dose

Delivered effluent dose

Type, number and duration of machine alarms and interruptions

Filter life


Name	Description	Reference

Integrative plasmid set with URA3 selection marker flanked with direct repeats

 pCfB126	pX-2-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB127	pX-3-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB128	pX-4-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB383	pXI-1-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB384	pXI-2-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB385	pXI-3-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB387	pXI-5-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB129	pXII-1-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB120	pXII-2-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB130	pXII-4-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB131	pXII-5-USER-URA3-DR	Mikkelsen et al. (2012)

 pCfB49	pXII-1-ccdB-USER-URA3-DR	Mikkelsen et al. (2012)

Plasmids that contain LoxP-flanked selection marker cassettes

 pUG6	LoxP-KanMX	Gueldener et al. (2002)

 pUG27	LoxP-SpHIS5	Gueldener et al. (2002)

 pUG72	LoxP-KlURA3	Gueldener et al. (2002)

 pUG73	LoxP-KlLEU2	Gueldener et al. (2002)

 pSA40	LoxP-CaLYS5	Ito-Harashima & McCusker (2004)

Episomal replication vectors with USER cassette (the vectors were derived from pESC vector series, Agilent)

 pCfB54	pESC-URA-ccdB-USER	This study

 pCfB55	pESC-HIS-ccdB-USER	This study

 pCfB132	pESC-URA-USER	This study

 pCfB291	pESC-HIS-USER	This study

 pCfB220	pESC-LEU-USER	This study

EasyClone integrative vector set with loxP-flanked selection markers

 pCfB255	pX-2-LoxP-KlURA3	This study

 pCfB353	pX-2-LoxP-KanMX	This study

 pCfB257	pX-3-LoxP-KlLEU2	This study

 pCfB258	pX-4-LoxP-SpHIS5	This study

 pCfB388	pXI-1-LoxP-KlLEU2	This study

 pCfB389	pXI-2-LoxP-KlURA3	This study

 pCfB390	pXI-3-LoxP-KlURA3	This study

 pCfB391	pXI-5-LoxP-SpHIS5	This study

 pCfB259	pXII-1-LoxP-KlLEU2	This study

 pCfB260	pXII-2-LoxP-CaLYS5	This study

 pCfB262	pXII-4-LoxP-SpHIS5	This study

 pCfB261	pXII-5-LoxP-SpHIS5	This study

Plasmids containing genes encoding fluorescent proteins

 pWJ1163	CFP	Reid et al. (2002)

 pWJ1165	YFP	Reid et al. (2002)

 pWJ1350	RFP	Lisby et al. (2003)

EasyClone vectors for expression of genes for fluorescent proteins in S. cerevisiae

 pCfB393	pX-2-LoxP-KlURA3-TEF1::CFP	This study

 pCfB394	pX-3-LoxP-KlLEU2-TEF1::RFP	This study

 pCfB395	pX-4- LoxP-SpHiS5-TEF1::YFP	This study

Episomal vectors for expression of genes for fluorescent proteins in S. cerevisiae

 pCfB396	pESC-URA-USER-TEF1::CFP	This study

 pCfB397	pESC-LEU-USER-TEF1::RFP	This study

 pCfB398	pESC-HIS-USER-TEF1::YFP	This study

Plasmid contains a cassette for expression of GFP in E. coli (used as positive control in USER cloning)

 pCfB774	pmExpCtrl	Dr Hao Lao, DTU

Name	Description	Reference

Integrative plasmid set with URA3 selection marker flanked with direct repeats

pCfB126	pX-2-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB127	pX-3-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB128	pX-4-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB383	pXI-1-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB384	pXI-2-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB385	pXI-3-USER-URA3-DR	Mikkelsen et al. (2012)

pCf	pXI-5-USER-URA3-	Mikkelsen et

Name	Description	Reference

B387	DR	al. (2012)

pCfB129	pXII-1-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB120	pXII-2-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB130	pXII-4-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB131	pXII-5-USER-URA3-DR	Mikkelsen et al. (2012)

pCfB49	pXII-1-ccdB-USER-URA3-DR	Mikkelsen et al. (2012)

Plasmids that contain LoxP-flanked selection marker cassettes

pUG6	LoxP-KanMX	Gueldener et al. (2002)

pUG27	LoxP-SpHIS5	Gueldener et al. (2002)

pUG72	LoxP-KlURA3	Gueldener et al. (2002)

pUG73	LoxP-KlLEU2	Gueldener et al. (2002)

pSA40	LoxP-CaLYS5	Ito-Harashima & McCusker (2004)

Episomal replication vectors with USER cassette (the vectors were derived from pESC vector series, Agilent)

pCfB54	pESC-URA-ccdB-USER	This study

pCfB55	pESC-HIS-ccdB-USER	This study

pCfB132	pESC-URA-USER	This study

pCfB291	pESC-HIS-USER	This study

pCfB220	pESC-LEU-USER	This study

EasyClone integrative vector set with loxP-flanked selection markers

pCfB255	pX-2-LoxP-KlURA3	This study

pCfB353	pX-2-LoxP-KanMX	This study

pCfB257	pX-3-LoxP-KlLEU2	This study

pCfB258	pX-4-LoxP-SpHIS5	This study

pCfB388	pXI-1-LoxP-KlLEU2	This study

pCfB389	pXI-2-LoxP-KlURA3	This study

pCfB390	pXI-3-LoxP-KlURA3	This study

pCfB391	pXI-5-LoxP-SpHIS5	This study

pCfB259	pXII-1-LoxP-KlLEU2	This study

pCfB260	pXII-2-LoxP-CaLYS5	This study

pCfB262	pXII-4-LoxP-SpHIS5	This study

pCfB261	pXII-5-LoxP-SpHIS5	This study

Plasmids containing genes encoding fluorescent proteins

pWJ1163	CFP	Reid et al. (2002)

pWJ1165	YFP	Reid et al. (2002)

pWJ1350	RFP	Lisby et al. (2003)

EasyClone vectors for expression of genes for fluorescent proteins in S. cerevisiae

pCfB393	pX-2-LoxP-KlURA3-TEF1::CFP	This study

pCfB394	pX-3-LoxP-KlLEU2-TEF1::RFP	This study

pCfB395	pX-4- LoxP-SpHiS5-TEF1::YFP	This study

Episomal vectors for expression of genes for fluorescent proteins in S. cerevisiae

pCfB396	pESC-URA-USER-TEF1::CFP	This study

pCfB397	pESC-LEU-USER-TEF1::RFP	This study

pCfB398	pESC-HIS-USER-TEF1::YFP	This study

Plasmid contains a cassette for expression of GFP in E. coli (used as positive control in USER cloning)

pCfB774	pmExpCtrl	Dr Hao Lao, DTU


	Specificity (%)

Roc 1 (Both H&R scores >0)	83.3

Roc 2 (Both H&R scores >1)	81.4

Roc 3 (Both H&R scores >2)	77.5

Roc 4 (Both H&R scores >3)	71.8


	PA-PRP (n = 11)	HA (n = 10)

Age, mean (SD) years	49.91 (13.72)	52.70 (10.30)

BMI, mean (SD) kg/m2	27.92 (11.94)	30.87 (5.64)

Previous surgery, no. (%)	5 (45 %)	8 (80 %)

Gender (Male), no. (%)	8 (72.73 %)	7 (70 %)

Symptom duration, mean (SD) years	8.50 (4.95)	15 (7.07)

Cause of osteoarthritis, no.

 Degeneration/unknown	6	4

 Post joint injury/surgery	3	3

 Sport related degeneration	2	3

Age, mean (SD) years

BMI, mean (SD) kg/m2

Previous surgery, no. (%)

Gender (Male), no. (%)

Symptom duration, mean (SD) years

Cause of osteoarthritis, no.

Degeneration/unknown

Post joint injury/surgery

Sport related degeneration


Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)

Physical	Psychological	Social	Spiritual

Biological markers	Absorption	Adjustment	Awareness

Disability	Anger	Advocacy	Balance

Energy	Anxiety	Economic	Enablement

Fatigue	Attitudes and Beliefs	 Health care utilization	Energy

Function/Activities of Daily Living	Awareness	 Cost-effectiveness	Harmony

Pain	Coping	Relationships	Hope

Pathology	Depression	Role function in daily life and work	Peace

Sleep	Empathy	Social support	Relaxation

Symptom management	Enablement	Socioeconomic	Spirituality

	Energy	Social Strain	Transformation

	Patient expectations	Religiosity

	General

	Hope

	Introversion

	Locus of control

	Mood

	Openness to experience

	Optimism/Pessimism

	Patient knowledge

	Patient motivation

	Patient perceived self-efficacy

	Patient perceptions of care

	Patient perceptions of risk

	Patient preference for control

	Patient Satisfaction

	Readiness

	Relaxation

	Resilience

	Self-Esteem

	Sense of Coherence

	Stress

	Trust

Quality of Life (assessing at least two of physical, psychological, social, spiritual)

Global

Multidimensional

Individualized

e.g. Measure Your Medical Outcome Profile, Measure Your Concerns and Well-being, Goal Attainment Scaling

Context of healing

Healing environment

Negotiations between patients and practitioners

Patient-centeredness of healing

Patient expectations

Patient-practitioner relationship

Practitioner attitudes towards integration

Practitioner attributes

Practitioner expectations

Practitioner experience

Attunement

Therapeutic Intent

Process of healing

Adjustment

Engagement with intervention experience

Personal growth

Transformation

Unstuckness

Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)

Patient expectations

Patient-practitioner relationship

Practitioner attitudes towards integration

Practitioner attributes

Practitioner expectations

Practitioner experience

Attunement

Therapeutic Intent

Process of healing

Adjustment

Engagement with intervention experience

Personal growth

Transformation

Unstuckness


Rotarix® label	"In the manufacturing process, porcine-derived materials are used.Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans."

RotaTeqTM label	"In the manufacturing process for RotaTeq, a porcine-derived material is used. DNA from porcine circoviruses (PCV) 1 and 2 has been detected in RotaTeq. PCV-1 and PCV-2 are not known to cause disease in humans."


Probe set ID	Gene Symbol	Gene Title	Fold Change in Apcfl/fl p53-/- v WT

1418368_at	Retnlb	resistin like beta	0.002

1422422_at	Defcr4	defensin related cryptdin 4	27.73

1425221_at	Agr3	anterior gradient homolog 3 (Xenopus laevis)	27.20

1460582_x_at	a	Nonagouti	17.82

1421837_at	Rps18	ribosomal protein S18	8.12

1422934_x_at	Defcr-rs7	defensin related cryptdin, related sequence 7	30.91

452183_a_at	Gtl2	GTL2, imprinted maternally expressed untranslated mRNA	25.82

1421838_at	Rps18	ribosomal protein S18	8.60

1459443_at	Kcnq1	Potassium voltage-gated channel, subfamily Q, member 1	9.67

1447260_at	ENSMUSG000000734	ENSMUSG00000073403	12.11

1426340_at	Slc1a3	solute carrier family 1 (glial high affinity glutamate transporter), member 3	13.83

1455274_at	a	Nonagouti	19.31

1422071_at	Lgals6	lectin, galactose binding, soluble 6	11.52

1420748_a_at	Adat1	adenosine deaminase, tRNA-specific 1	4.33

1423017_a_at	Il1rn	interleukin 1 receptor antagonist	12.54

1449492_a_at	Lect2	leukocyte cell-derived chemotaxin 2	43.73

1443536_at	Slc7a11	solute carrier family 7 (cationic amino acid transporter, y+ system), member 11	13.16

1446728_at	D3Ertd797e	DNA segment, Chr 3, ERATO Doi 797, expressed	2.39

1459779_s_at	Setd8	SET domain containing (lysine methyltransferase) 8	6.92

1421257_at	Pigb	phosphatidylinositol glycan anchor biosynthesis, class B	11.65

1446730_at	C79267	Expressed sequence C79267	10.65

1459834_x_at	---	---	4.64

1460604_at	Cybrd1	cytochrome b reductase 1	22.55

1427580_a_at	Rian	RNA imprinted and accumulated in nucleus	9.54

1418708_at	Apoc4	apolipoprotein C-IV	19.03

1422597_at	Mmp15	matrix metallopeptidase 15	10.55

1434734_at	E130016E03Rik	RIKEN cDNA E130016E03 gene	9.11

1441594_at	---	---	5.86

1441624_at	Sorbs2	sorbin and SH3 domain containing 2	3.78

1434028_at	Arnt2	aryl hydrocarbon receptor nuclear translocator 2	11.43

1427967_at	Srgap2	SLIT-ROBO Rho GTPase activating protein 2	9.36

1434497_at	4933431E20Rik	RIKEN cDNA 4933431E20 gene	7.73

1444538_at	Snd1	Staphylococcal nuclease and tudor domain containing 1	8.68

1457636_x_at	---	---	5.12

1436845_at	Axin2	axin2	4.58

1457262_at	2610207I05Rik	RIKEN cDNA 2610207I05 gene	5.35

1431031_at	Arid4b	AT rich interactive domain 4B (Rbp1 like)	3.55

1439380_x_at	Gtl2	GTL2, imprinted maternally expressed untranslated mRNA	7.69

1417520_at	Nfe2l3	nuclear factor, erythroid derived 2, like 3	6.40

1446376_at	Rps6kb1	ribosomal protein S6 kinase, polypeptide 1	5.88

1422882_at	Sypl	synaptophysin-like protein	4.91

1444498_at	---	---	7.23

1438258_at	Vldlr	very low density lipoprotein receptor	6.85

1422954_at	Zfp60	zinc finger protein 60	3.25

1425986_a_at	Dcun1d	DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae)	2.49

1430458_at	Supt6h	suppressor of Ty 6 homolog (S. cerevisiae)	3.17

1434734_at	E130016E03Rik	RIKEN cDNA E130016E03 gene	9.11

1435082_at	Syp1	synaptophysin-like protein	5.30

1437065_at	Zbtb20	zinc finger and BTB domain containing 20	12.39

1441487_at	Trim2	tripartite motif protein 2	5.68

1443628_at	---	---	9.06

1447386_at	Usp2	Ubiquitin specific peptidase 8	2.94

1455327_at	Senp2	SUMO/sentrin specific peptidase 2	4.36

Probe set ID	Gene Symbol	Gene Title

1418368_at	Retnlb	resistin like beta

1422422_at	Defcr4	defensin related cryptdin 4

1425221_at	Agr3	anterior gradient homolog 3 (Xenopus laevis)

1460582_x_at	a	Nonagouti

1421837_at	Rps18	ribosomal protein S18

1422934_x_at	Defcr-rs7	defensin related cryptdin, related sequence 7

452183_a_at	Gtl2	GTL2, imprinted maternally expressed untranslated mRNA

1421838_at	Rps18	ribosomal protein S18

1459443_at	Kcnq1	Potassium voltage-gated channel, subfamily Q, member 1

1447260_at	ENSMUSG000000734	ENSMUSG00000073403

1426340_at	Slc1a3	solute carrier family 1 (glial high affinity glutamate transporter), member 3

1455274_at	a	Nonagouti

1422071_at	Lgals6	lectin, galactose binding, soluble 6

1420748_a_at	Adat1	adenosine deaminase, tRNA-specific 1

1423017_a_at	Il1rn	interleukin 1 receptor antagonist

1449492_a_at	Lect2	leukocyte cell-derived chemotaxin 2

1443536_at	Slc7a11	solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

1446728_at	D3Ertd797e	DNA segment, Chr 3, ERATO Doi 797, expressed

1459779_s_at	Setd8	SET domain containing (lysine methyltransferase) 8

1421257_at	Pigb	phosphatidylinositol glycan anchor biosynthesis, class B

1446730_at	C79267	Expressed sequence C79267

1459834_x_at	---	---

1460604_at	Cybrd1	cytochrome b reductase 1

1427580_a_at	Rian	RNA imprinted and accumulated in nucleus

1418708_at	Apoc4	apolipoprotein C-IV

1422597_at	Mmp15	matrix metallopeptidase 15

1434734_at	E130016E03Rik	RIKEN cDNA E130016E03 gene

1441594_at	---	---

1441624_at	Sorbs2	sorbin and SH3 domain containing 2

1434028_at	Arnt2	aryl hydrocarbon receptor nuclear translocator 2

1427967_at	Srgap2	SLIT-ROBO Rho GTPase activating protein 2

1434497_at	4933431E20Rik	RIKEN cDNA 4933431E20 gene

1444538_at	Snd1	Staphylococcal nuclease and tudor domain containing 1

1457636_x_at	---	---

1436845_at	Axin2	axin2

1457262_at	2610207I05Rik	RIKEN cDNA 2610207I05 gene

1431031_at	Arid4b	AT rich interactive domain 4B (Rbp1 like)

1439380_x_at	Gtl2	GTL2, imprinted maternally expressed untranslated mRNA

1417520_at	Nfe2l3	nuclear factor, erythroid derived 2, like 3

1446376_at	Rps6kb1	ribosomal protein S6 kinase, polypeptide 1

1422882_at	Sypl	synaptophysin-like protein

1444498_at	---	---

1438258_at	Vldlr	very low density lipoprotein receptor

1422954_at	Zfp60	zinc finger protein 60

1425986_a_at	Dcun1d	DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae)

1430458_at	Supt6h	suppressor of Ty 6 homolog (S. cerevisiae)

1434734_at	E130016E03Rik	RIKEN cDNA E130016E03 gene

1435082_at	Syp1	synaptophysin-like protein

1437065_at	Zbtb20	zinc finger and BTB domain containing 20

1441487_at	Trim2	tripartite motif protein 2

1443628_at	---	---

1447386_at	Usp2	Ubiquitin specific peptidase 8

1455327_at	Senp2	SUMO/sentrin specific peptidase 2


Acridine orange	A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.

Acriflavine	3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication.

Aminacrine	A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.

Amsacrine	Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.

Ethacridine	A topically applied anti-infective agent.

Nitracrine	Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.

Proflavine	3,6-Diaminoacridine. Topical antiseptic used mainly in wound dressings.

Tacrine	A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.

Quinacrine	An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions as well as a form of contraception/sterilization. It is used in cell biological experiments as an inhibitor of phospholipase A2.

Acridine orange	A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.

Acriflavine	3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication.

Aminacrine	A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.

Amsacrine	Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.

Ethacridine	A topically applied anti-infective agent.

Nitracrine	Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.

Prof	3,6-Diaminoacridine. Topical antiseptic used ma

lavine	inly in wound dressings.

Tacrine	A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.

Quinacrine	An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions as well as a form of contraception/sterilization. It is used in cell biological experiments as an inhibitor of phospholipase A2.


 	Drug(s) resistant to	Typical diseases

Name of Bacterium

 Escherichia coli  	Cephalosporins and fluoroquinolones	Urinary tract infections and blood stream infections

 Klebsiella pneumoniae 	Cephalosporins and carbapenems	Pneumonia, blood stream, and urinary tract infections

 Staphylococcus aureus 	Methicillin	Wound and blood stream infections

 Streptococcus pneumoniae 	Penicillin	Pneumonia, meningitis, and otitis

 Nontyphoidal Salmonella 	Fluoroquinolones	Foodborne diarrhoea, blood stream infections

 Shigella species 	Fluoroquinolones	Diarrhoea (bacillary dysentery)

 Neisseria gonorrhoeae 	Cephalosporins	Gonorrhoea

 Mycobacterium tuberculosis 	Rifampicin, isoniazid, and fluoroquinolone [4]	Tuberculosis

Name of Fungi

 Candida spp.	Fluconazole and echinocandins [5]	Candidiasis

 Cryptococcus neoformans	Fluconazole [17]	Cryptococcosis

 Aspergillus spp.	Azoles [18]	Aspergillosis

 Scopulariopsis spp.	Amphotericin B, flucytosine, and azoles [19]	Onychomycosis

Name of Virus

 Cytomegalovirus (CMV)	Ganciclovir and foscarnet [20]	In AIDS and oncology patients

 Herpes simplex virus (HSV)	Acyclovir, famciclovir, and valacyclovir [21]	Herpes simplex

 Human immunodeficiency

 virus (HIV)	Antiretroviral drugs [22]	AIDS

 Influenza virus	Adamantane derivatives (Amantadine and rimantadine) and neuraminidase inhibitors [23]	Influenza

 Varicella zoster virus 	Acyclovir and valacyclovir [21]	Chicken pox

 Hepatitis B virus (HBV)	Lamivudine [24]	Hepatitis B

Name of Parasite

 Plasmodia spp. 	Chloroquine, artemisinin, and atovaquone [25]	Malaria

 Leishmania spp.	Pentavalent antimonials, miltefosine, paromomycin, and amphotericin B [13, 14]	Leishmaniasis

 Schistosomes 	Praziquantel and oxamniquine [26, 27]	Schistosomiasis

 Entamoeba 	Metronidazole [28]	Amoebiasis

 Trichomonas vaginalis 	Nitroimidazoles [29]	Trichomoniasis

 Toxoplasma gondii 	Artemisinin, atovaquone, and sulfadiazine [10–12]	Toxoplasmosis


 	Frequency	Percentage

Aetiology

 Unknown	294	66.2%

 Stone	44	9.9%

 Nephrotic	22	5.0%

 Glomerulonephritis (nephritic)	22	5.0%

 Obstructive uropathy	9	2.0%

 SSK (small shrunken kidneys)	28	6.3%

 Others (Wilms, BOO, gastroenteritis, etc.)	22	5.0%

 VUR (vesicoureteral reflux)	3	.7%

Hepatitis B

 Positive	11	2.5%

 Negative	433	97.5%

Hepatitis C

 Positive	13	2.9%

 Negative	431	97.1%

	Frequency	Percentage

VUR (vesicoureteral reflux)	3	.7%

Hepatitis B

Positive	11	2.5%

Negative	433	97.5%

Hepatitis C

Positive	13	2.9%

Negative	431	97.1%


Characteristic	LN group (n = 14)	P-value

Time since birth of first male child (yr)

 1 to 15 (n = 5)	9.25 ± 12.37	NS

 >15 (n = 9)	5.5 ± 9.6

Time since SLE diagnosis (yr)

 1 to 5 (n = 5)	10 ± 13.6	NS

 >5 (n = 9)	5.08 ± 8

Number of male pregnancies

 1 (n = 0)	7.99 ± 10.75	NS

 >1 (n = 4)	3.7 ± 7.5

Serum creatinine (mg/dl)

 ≤1.5 mg/dl (n = 10)	9.5 ± 11.2	0.026

 >1.5 mg/dl (n = 3)	0.12 ± 0.2

Characteristic	LN group (n = 14)	P-value

Time since birth of first male child (yr)

1 to 15 (n = 5)	9.25 ± 12.37	NS

>15 	5.


Methodology Followed	Start/End Point Needed	Tube Specific	No Automation	Seed Point Needed	time to detection	Surgical planning	Neuro-surgical planning	Arbitrary objects detection	Arbitrary image modality	Fine Vessel Accuracy	Main vessel Accuracy	Center-Line-Detection Accuracy	Module complexity	Feature Complexity

m1	y	n	y	y	gt	Y	Y	n	y	gt	lt	y	gt	Lt

m2	y	y	y	n	gt	Y	y	y	y	gt	gt	lt	lt	eq

m3	y	y	n	n	gt	n	n	y	y	lt	eq	eq	lt	lt

m4	y	n	n	n	lt	y	y	y	y	lt	lt	eq	lt	lt

m5	y	n	y	y	gt	n	n	y	y	lt	y	lt	lt	lt

m6	n	y	n	n	eq	y	y	n	y	eq	eq	eq	eq	eq


No.	Activity reviewed	Activities confirmed (Pa)	Additional predicted activities (Paa)

78	Antimicrobial antiviral antineoplastic	Antineoplastic (sarcoma) (0.413)	Atherosclerosis treatment (0.924)Genital warts treatment (0.600)

79	Cytotoxic antineoplastic	Antineoplastic (0.584)Antineoplastic (liver cancer) (0.797)	Endothelial growth factor antagonist (0.885)Angiogenesis inhibitor (0.632)

80	Not studied	–	Phobic disorders treatment (0.728)Antineurotic (0.685)

81	Not studied	–	Antineurotic (0.694)Phobic disorders treatment (0.648)

82	Not studied	–	Lysase stimulant (0.787)Kidney function stimulant (0.518)

83	Not studied	–	Lysase stimulant (0.787)Kidney function stimulant (0.518)

84	Interleukin 4 antagonist	–	Antiseborrheic (0.815)Kidney function stimulant (0.721)Phobic disorders treatment (0.749)

85	Antibacterial	–	Antineurotic (0.806)Phobic disorders treatment (0.752)

86	Not studied	–	Not predicted: MolCharge: 1

87	Not studied	–	Not predicted: MolCharge: 1

88	Cytotoxic	Antineoplastic (0.666)Antineoplastic (renal cancer) (0.614)	Pterin deaminase inhibitor (0.989)Natural killer cell stimulant (0.587)

89	Cytotoxic antifungal	–	Antiallergic (0.765)Cytostatic (0.712)Erythropoiesis stimulant (0.692)

90	Antineoplastic antileukemic	Antineoplastic (0.749)Antileukemic (0.622)	Genital warts treatment (0.936)DNA synthesis inhibitor (0.825)Cytostatic (0.701)

91	Antineoplastic antileukemic	Antineoplastic (0.752)Antileukemic (0.634)	Antimetabolite (0.938)DNA synthesis inhibitor (0.926)Neuroprotector (0.910)

92	Antibiotic	–	Antineoplastic (sarcoma) (0.730)

93	Not studied	–	Antineoplastic(0.768)Antibacterial (0.614)Antifungal (0.592)

94	Antimicrobial antiviral antineoplastic	Glycopeptide-like antibiotic (0.627)Antineoplastic(0.406)	Analgesic (0.637)

95	Antimicrobial antiviral antineoplastic	Glycopeptide-like Antibiotic (0.714)Antineoplastic (0.519)Antibacterial (0.409)	Analgesic (0.670)

96	Antimicrobial antiviral antineoplastic	Glycopeptide-like antibiotic (0.625)Antineoplastic(0.443)	Analgesic (0.601)

97	Antimicrobial antiviral antineoplastic	Glycopeptide-like antibiotic (0.713)Antineoplastic (0.547)Antibacterial (0.424)	Analgesic (0.641)


Mobile phase	Relation	Volume (mL)	Fractions	Residue (mg)

Dichloromethane	100%	500	F4.3.1	0.4

Dichloromethane : ethyl acetate	90 : 10	500	F4.3.2	3

F4.3.3	59

F4.3.4	91

Dichloromethane : ethyl acetate	80 : 20	500	F4.3.5	256

F4.3.6	65

Dichloromethane : ethyl acetate	60 : 40	500	F4.3.7 	146

F4.3.8	8

Dichloromethane : ethyl acetate	40 : 60	500	F4.3.9	6

F4.3.10	111

Dichloromethane : ethyl acetate	20 : 80	500	F4.3.11	63

Ethyl acetate	100%	500	F4.3.12	3

Dichloromethane : ethyl acetate	90 : 10	500	F4.3.3	59

F4.3.4	91

Dichloromethane : ethyl acetate	80 : 20	500	F4.3.5	256

F4.3.6	65

Dichloromethane : ethyl acetate	60 : 40	500	F4.3.7	146

F4.3.8	8

Dichloromethane : ethyl acetate	40 : 60	500	F4.3.9	6

F4.3.10	111

Dichloromethane : ethyl acetate	20 : 80	500	F4.3.11	63

Ethyl acetate	100%	500	F4.3.12	3


	Total (N)	N of Death	Median survival (months)*	Mean survival (months)	P value

Oct-4

Positive	58	26	43	45.1	0.022

Negative	36	8	*	42.4

Sox2

Positive	53	25	43	35.1	0.023

Negative	41	9	*	62.5

Gli1

Positive	50	22	43	47.1	0.045

Negative	44	12	*	40.9

CD44

Positive	40	24	30	37.7	0.000

Negative	54	10		43.5

CD133

Positive	31	14	43	33.7	0.124

Negative	63	20	*	57.3

p-AKT

Positive	78	30	*	53.3	0.300

Negative	16	4	46	41.7

p-ERK

Positive	36	18	34	33.4	0.014

Negative	58	16	*	57.5

	Total (N)	N of Death	Median survival (months)*	Mean survival (months)	P value

Sox2

Positive	53	25	43	35.1	0.023

Negative	41	9	*	62.5

Gli1

Positive	50	22	43	47.1	0.045

Negative	44	12	*	40.9

CD44

Positive	40	24	30	37.7	0.000

Negative	54	10		43.5

CD133

Positive	31	14	43	33.7	0.124

Negative	63	20	*	57.3

p-AKT

Positive	78	30	*	53.3	0.300

Negative	16	4	46	41.7

p-ERK

Positive	36	18	34	33.4	0.014

Negative	58	16	*	57.5


Ref.	Textural features	Classifier	Accuracy

Mannivannan [23]	Four types of local features with CPM-BoW encoding	Ensemble SVMs	87.09%

Sansone [87]	Dense local descriptors with BoW encoding	SVM	83.64%

Theodorakopoulos [88]	SIFT with VLAD encoding, LBP-based and morphological descriptors	SVM	83.33%

Gao [89]	Raw image data with deep CNNs	Deep CNNs	83.23%

Paisitkriangkrai [90]	Combination of different sets of low-level texture features	Boosting classifier	81.55%

Ensafi [91]	SIFT and SURF descriptors with BoW sparse encoding	SVM	80.81%

Nanni [92]	LBP-derived and morphological features	SVM	78.27%

Codrescu [93]	Raw image data	Neural networks	74.93%

Taormina [94]	Combination of different types of local texture features	kNN	74.62%

Ponomarev [95]	Morphological and shape descriptors	SVM	73.53%

Roberts [90]	Wavelet transform-based features	SVM	66.99%


Compounds	Signals	Assign of Signals

CTX3C	H	Hydroxyl group 44

I	Olefin 2, 3, 13, 14, 18, 19, 23, 24

J	17-H

51OHCTX3C	K	17-H

L	38, 42-H

M	22, 25-H

N	17-H


Termb	KEGG pathway	Countc	%d	Detected proteome backgrounde	Entire proteome backgroundf

P‐value	Fold enrichment	P‐value	Fold enrichment	Bonferroni

In nonproducing condition (325 DAVID IDs in the 1396 detected proteome)

cgl00020	Citrate cycle (TCA cycle)	15	4.6	4.98E‐06	2.9	2.59E‐12	9.3	4.02E‐10

cgl00970	Aminoacyl‐tRNA biosynthesis	15	4.6	0.00 579	1.9	1.03E‐09	7.0	1.59E‐07

cgl03010	Ribosome	26	8.0	0.00 582	1.6	1.98E‐10	4.2	3.07E‐08

In glutamate‐producing condition (213 DAVID IDs in the 1181 detected proteome)

cgl03010	Ribosome	24	12.1	0.00 101	1.8	1.18E‐11	5.2	1.48E‐09

cgl00020	Citrate cycle (TCA cycle)	11	4.7	0.00 191	2.6	2.84E‐08	9.3	3.58E‐06

cgl00970	Aminoacyl‐tRNA biosynthesis	13	6.1	0.00 541	2.2	5.11E‐09	8.2	6.44E‐07

209 proteins that contain reproducible and more than 2‐fold changed acetylation sites

cgl00020	Citrate cycle (TCA cycle)	11	5.3	1.09E‐04	3.6	3.65E‐09	11.4	4.63E‐07


CSX (−)MetX (−)(N = 39)	CSX (+)MetX (−)(N = 35)	CSX (−)MetX (+)(N = 15)	CSX (+)MetX (+)(N = 24)	pa	pb


The 4 ALSI factors	Number of Questions	Mean	Mean as % of Max.	SEM	Cronbach’s α

Deep approach	6 Questions	19.84	66.10	0.22	0.71

Surface approach	4 Questions	9.57	47.85	0.15	0.64

Effort management /Organised studying	4 Questions	13.02	65.10	0.18	0.74

Monitoring studying	4 Questions	13.70	68.50	0.15	0.58

The 4 ALSI factors	Number of Questions	Mean	Mean as % of Max.

Deep approach	6 Questions	19.84	66.10

Surface approach	4 Questions	9.57	47.85

Effort management /Organised studying	4 Questions	13.02	65.10

Monitoring studying	4 Questions	13.70	68.50


Variable	RR (CI 95%)	p value*

Diabetes mellitus	1.3 (0.8–2)	0.2

Hepatopathy	4 (2.7–5.9)	< 0.001

Exposure to chemotherapy	1.6 (0.9–2.7)	0.1


Energy intake (kcal/day) B (95 %-CI)	Standard. Beta (95 %-CI)	P-value	Satiety Response (score) B (95 %-CI)	Standard. Beta (95 %-CI)	P-value


Variable	Category	OR	95% CI

Age (ref: < 50 years)	> 50 years	0.49	0.09, 2.61

Gender (ref: male)	Female	0.52	0.11, 2.61


	Serotonin	RANKL	P1NP	CTX

OVX+Saline versus SHAM+Saline	34.8% ###	77.6% ###	106% ###	74.4% ###

OVX+WBV versus SHAM+Saline	4.9%	4.6%	0.1%	42.7% ###

OVX+ALN versus SHAM+Saline	30.3% ###	1.2%	-6.1%	40.8% ###


Item	Treatmentb	Pooled SEM	Contrastc

	Control	LPS	LPS + Low GLP-2	LPS + High GLP-2	1	2	3

Duodenum, g	17.8	15.2	17.4	17.9	0.4	0.008	0.019	0.005

Jejunum, g	325	287	323	342	7	0.034	0.042	0.003


SCD incidence rates per 100.000 person years	All	Men	Women	Incidence rate ratio	p-value

19–35 years	4.4 (3.9–4.8)	5.9 (5.3–6.5)	2.8 (2.4–3.2)	2.1 (1.8–2.6)	<0.01


Parameter	Healthy donors	RCC patients	Patients < pT3	Patients ≥ pT3

Number of leukocytes	6,260 ± 310	7,005 ± 350	6,500 ± 402	8,340 ± 563

Granulocytes	4,227 ± 310	5,103 ± 292	4,702 ± 354	6,139 ± 385

Monocytes	351 ± 39	375 ± 21	349 ± 22	441 ± 42

Dendritic cells (DC)	19 ± 2	16 ± 1	17 ± 1	13 ± 2

Lymphocytes	1,670 ± 111	1,566 ± 103	1,490 ± 110	1,760 ± 237

Neutrophil-to-lymphocyte ratio (NLR)	2.86 ± 0.37	3.93 ± 0,40	3.8 ± 0.5	4.27 ± 0.64

Granulocyte/DC ratio	249.4 ± 25	378.7 ± 31	318.1 ± 30	535.4 ± 60


Rank	Active substance, drug formulation	No of prescriptions	Potentially harmful or known to be harmful excipients

1	Gentamicin, inj solution	200	Parabens, sodium metabisulphite

2	Simeticone, oral suspension	108	Sodium benzoate, saccharin sodium, silicium dioxide, sodium cyclamate, sorbic acid

3	Heparin, inj solution	86	Benzyl alcohol, parabens

4	Laurilsulphate + Sorbitol + Sodium citrate, rectal solution	60	Sorbic acid

5	Salbutamol, nebulisation solution	54	Benzalkonium chloride, propylene glycol

6	Dobutamine, inj solution	45	Sodium metabisulphite

7	Epinephrine, inj solution	36	Sodium metabisulphite

8	Iron, oral solution	32	Parabens, saccharin sodium

9	Budesonide, nebulisation solution	31	Polysorbate 80, disodiumedetate

10	Chloramphenicol, opthalmic solution	29	Benzalkonium chloride, polysorbate 80, borax, boric acid

11	Caffeine, solution	29	Sodium benzoate

12	Phenobarbital, tablet	29	Silicium dioxide, gelatin

13	Paracetamol, suppository	29	Disodium hydrogen phosphate

14	Piperacillin + tazobactam, inj solution	25	Disodium edetate

15	Paracetamol, inj solution	24	Disodium hydrogen phosphate

16	Hydrocortisone, inj solution	23	Benzyl alcohol, disodium hydrogen phosphate

17	Epoetin beta, inj solution	22	Disodium hydrogen phosphate, glycine, calcium chloride dihydrate, leucine,

18	Ibuprofen, inj solution	21	Trometamol

19	Hyoscine butylbromide, tablet	20	Silicium dioxide

20	Spironolactone, tablet	18	Silicium dioxide

21	Zidovudine, oral solution	17	Sodium benzoate, saccharin sodium

22	Fusidic acid, ophthalmic solution	16	Benzalkonium chloride, disodium edetate

23	Morphine, inj solution	14	Sodium metabisulphite

24	Phenobarbital, inj solution	13	Benzyl alcohol, propylene glycol

25	Heparin sodium, topical gel	12	Parabens, ethanol, trietanolamine,

26	Insulin, inj solution	11	Cresol

Active substance, drug formulation	No of prescriptions	Potentially harmful or known to be harmful excipients

Gentamicin, inj solution	200	Parabens, sodium metabisulphite

Simeticone, oral suspension	108	Sodium benzoate, saccharin sodium, silicium dioxide, sodium cyclamate, sorbic acid

Heparin, inj solution	86	Benzyl alcohol, parabens

Laurilsulphate + Sorbitol + Sodium citrate, rectal solution	60	Sorbic acid

Salbutamol, nebulisation solution	54	Benzalkonium chloride, propylene glycol

Dobutamine, inj solution	45	Sodium metabisulphite

Epinephrine, inj solution	36	Sodium metabisulphite

Iron, oral solution	32	Parabens, saccharin sodium

Budesonide, nebulisation solution	31	Polysorbate 80, disodiumedetate

Chloramphenicol, opthalmic solution	29	Benzalkonium chloride, polysorbate 80, borax, boric acid

Caffeine, solution	29	Sodium benzoate

Phenobarbital, tablet	29	Silicium dioxide, gelatin

Paracetamol, suppository	29	Disodium hydrogen phosphate

Piperacillin + tazobactam, inj solution	25	Disodium edetate

Paracetamol, inj solution	24	Disodium hydrogen phosphate

Hydrocortisone, inj solution	23	Benzyl alcohol, disodium hydrogen phosphate

Epoetin beta, inj solution	22	Disodium hydrogen phosphate, glycine, calcium chloride dihydrate, leucine,

Ibuprofen, inj solution	21	Trometamol

Hyoscine butylbromide, tablet	20	Silicium dioxide

Spironolactone, tablet	18	Silicium dioxide

Zidovudine, oral solution	17	Sodium benzoate, saccharin sodium

Fusidic acid, ophthalmic solution	16	Benzalkonium chloride, disodium edetate

Morphine, inj solution	14	Sodium metabisulphite

Phenobarbital, inj solution	13	Benzyl alcohol, propylene glycol

Heparin sodium, topical gel	12	Parabens, ethanol, trietanolamine,

Insulin, inj solution	11	Cresol


Risk factors	Incisional SSI (+)	Incisional SSI (−)	β	SE	Hazard ratio (95 % CI)	p value


	HV	NU	P values

n	35	33

Age [median (range)]	32 (23–78)	44 (18–78)	0.004

Sexe (% of female)	62 %	31 %	0.003

BMI [median (range)]	26.1 (20.5–31.1)	26.8 (18.8–37.1)	NS

Smokers	28 %	58 %	0.03

Daily alcohol	0 %	29 %	0.003

Comorbidities

Fracture history in the past year of visit	6 %	100 %	<0.001

Rheumatic diseases (osteoarthritis, psoriatic arthritis and rheumatoid arthritis)	0 %	14 %	NS

Gastric (heartburn and esophagitis)	0 %	14 %	NS

Diabetes (NIDDM)	0 %	10 %	NS

Pulmonary (asthma, emphysema, chronic pulmonary disease, pneumothorax)	0 %	24 %	0.006

Cardiovascular (ischaemia, deep vein thrombosis, infarction)	0 %	14 %	NS

High blood pressure	0 %	17 %	NS

Hypercholesterolemia	0 %	17 %	NS

Hypothyroidism	0 %	0 %	NS

Hypovitamin D	0 %	3 %	NS

Treatment

NSAID and/or analgesic and/or tramadol	0 %	100 %	<0.001

Anxiolytics	0 %	33 %	<0.001

	HV	NU	P values

n	35	33

Age [median (range)]	32 (23–78)	44 (18–78)	0.004

Sexe (% of female)	62 %	31 %	0.003

BMI [median (range)]	26.1 (20.5–31.1)	26.8 (18.8–37.1)	NS

Smokers	28 %	58 %	0.03

Daily alcohol	0 %	29 %	0.003

Comorbidities

Fracture history in the past year of visit	6 %	100 %	<0.001

Rheumatic diseases (osteoarthritis, psoriatic arthritis and rheumatoid arthritis)	0 %	14 %	NS

Gastric (heartburn and esophagitis)	0 %	14 %	NS

Diab	0 	1	N

	HV	NU	P values

etes (NIDDM)	%	0 %	S

Pulmonary (asthma, emphysema, chronic pulmonary disease, pneumothorax)	0 %	24 %	0.006

Cardiovascular (ischaemia, deep vein thrombosis, infarction)	0 %	14 %	NS

High blood pressure	0 %	17 %	NS

Hypercholesterolemia	0 %	17 %	NS

Hypothyroidism	0 %	0 %	NS

Hypovitamin D	0 %	3 %	NS

Treatment

NSAID and/or analgesic and/or tramadol	0 %	100 %	<0.001

Anxiolytics	0 %	33 %	<0.001


	Transitions	Transversions

	A/G	C/T	A/C	A/T	G/C	G/T

Numbers of allelic sites	1,466	1,430	463	463	423	473

Percentage of allelic sites	31.07%	30.31%	9.81%	9.81%	8.97%	10.03%

Total (Percentage)	2,896 (61.38%)	1,822 (38.62%)


 	IFN-beta clinical response	EDSS*	Relapses**

 	N	Resp.	%

MHC2TA mRNA level decreased + HHV-6 in serum	21	5	23.8	1.5	1.2

MHC2TA mRNA level increased without HHV-6 in serum	99	58	58.6	- 0.5	0.4

p	 	0.004


SN	Age	Vaccine

1	Birth (0–11 Months)	BCG

2	Birth (as soon as possible within 14 days of life	OPV0

3	6 Weeks	Pentavalent 1, OPV1

4	10 Weeks	Pentavalent 2, OPV2

5	14 Weeks	Pentavalent 3, OPV3

6	9 Months	Measles, OPV4

7	18 Months	Measles

SN	Age

1	Birth (0–11 Months)

2	Birth (as soon as possible within 14 days of life

3	6 Weeks

4	10 Weeks

5	14 Weeks

6	9 Months

7	18 Months

Vaccine

BCG

OPV0

Pentavalent 1, OPV1

Pentavalent 2, OPV2

Pentavalent 3, OPV3

Measles, OPV4

Measles


Gene	Primer sequence		Base pairs	Source

18S	Forward sequence	TGG TCG CTC GCT CCT CTC C	360	NR_003286

	Reverse sequence	CGC CTG CTG CCT TCC TTG G

αSMA	Forward sequence	GTG TGA GGA AGA GGA CAG CA	446	X60732

	Reverse sequence	TAC GTC CAG AGG CAT AGA GG

Collagen I	Forward sequence	GAT GCG TTC CAG TTC GAG TA	312	Personal communication

	Reverse sequence	GGT CTT CCG GTG GTC TTG TA

Collagen III	Forward sequence	TTA TAA ACC AAC CTC TTC CT	255	Personal communication

	Reverse sequence	TAT TAT AGC ACC ATT GAG AC

COX-2	Forward sequence	CAA ACT GCT CCT GAA ACC CAC TC	82	NM_001082388

	Reverse sequence	GCT ATT GAC GAT GTT CCA GAC TCC

IL-1β	Forward sequence	GCC GAT GGT CCC AAT TAC AT	121	M26295

	Reverse sequence	ACA AGA CCT GCC GGA AGC T

IL-6	Forward sequence	CCT GCC TGC TGA GAA TCA CTT	51	AF469048

	Reverse sequence	CGA GAT ACA TCC GGA ACT CCA T

IL-8	Forward sequence	CAA CCT TCC TGC TGT CTC TG	145	NM_001082293

	Reverse sequence	GGT CCA CTC TCA ATC ACT CT

iNOS	Forward sequence	CTG TGA CGT CCA GCG CTA CA	119	AF469048

	Reverse sequence	GCA CGG CGA TGT TGA TCT CTC GCC CT

PRG4	Forward sequence	GAA CGT GCT ATA GGA CCT TC	287	NM_00127709

	Reverse sequence	CAG ACT TTG GAT AAG GTC TGC C

TGF-β	Forward sequence	CGG CAG CTG TAC ATT GAC TT	271	AF000133

	Reverse sequence	AGC GCA CGA TCA TGT TGG AC

TNF-α	Forward sequence	TCT AGT CAA CCC TGT GGC CC	51	NM_00108

	Reverse sequence	GCC CGA GAA GCT GAT CTG AG


Exercise	Description

Exercise 1Relaxing	Diaphragmatic breathing and postural elements such as alignment of the midline.The patient is supine on a mat with flexed knees and arms along the chest.

Exercise 2Raising arm, opening and closing punches	Lying on the bed, arms at sides, flexed knees. Slowly, lift parallel the arms till the upright position, opening and clenching the fists in order to contract the muscles of the arms. Maintain up the position, opening and closing the punches five times, and return to the starting position. Repeat ten times.

Exercise 3Stretching and releasing the arms. Recovery of the flexion.	Lying on the bed, flexed knees. Interlock the fingers and slowly bring to full flexion and then on the pillow; then put as much as possible while keeping your arms extended. Perform the technique of breathing for a minute. Repeat ten times.

Exercise 4 Turn the shoulders. Rotation-anteropulsion-retropulsion	Standing or sitting, rotate the shoulders for ten times.

Exercise 5Abduction and adduction of the arms—isometric strengthening	Lying or standing, bring the arms out, with extended elbows. Maintain the position for six seconds. Return to the starting position, slowly. Repeat for ten times.

Exercise 6Opening and closing elbows	Standing, legs apart. Place both hands on the hips with thumbs pointing backwards. Push your elbows back and forth without moving the hands. Repeat for ten times.

Exercise 7Run up the wall—recovery of flexion	Getting closer to the maximum height possible completely to the wall, stopping for few seconds, and trying to gently remove the hands from the wall. Repeat ten times.

Exercise 8Run up the wall by the side—recovery of abduction	With a bit of tape, standing with the unaffected side facing the wall, place the hand on the wall at shoulder height. Reaching a point with his hand, as high as possible, marking it with the piece of tape. Begin the exercise with the operated arm, and repeat ten times trying to get closer to the mark left on the wall.

Exercise 9Hand on the operated shoulder—recovery of the adduction	Sitting or standing, arms along the sides. Bring the hand of the operated limb to the contralateral shoulder. Return to starting position. Repeat ten times.

Exercise 10Rotate the arms—promoting the rotations	Standing with legs apart, raise your arms to the shoulder. Beginning with small movements, gradually increase the diameter up to do it without complaints. We recommend at least five full rotations. Finally, bring the arm down the side and remain at rest for a moment.

Exercise 11Run up the back—promoting the extension and intrarotation	Standing, place the hands behind the back and take with the healthy hand, the hand of the operated limb. Slowly slide the hands along the spine upwards to its possible and maintain the position for a few seconds. Then decline slowly. Repeat for ten times.

Exercise 12Opening and closing the elbows	Standing or sitting, with the feet firmly on the ground, interlock the hands ahead of face with the head upright. Slowly, raise the arms above the head and then behind the neck. Then open both elbows and close them for five times. If you feel discomfort at the wound, keep the position and work with the breathing.

Exercise 13Bar	Sitting or standing, hold the bar (about 110 cm long). Bring the arms forward and upward at the elbows extended. Flex elbows and bring the bar behind the head. Return slowly to starting position. Repeat ten times.

Exercise 14Codman's pendulum 	Lying on a bed in a prone position, the arm perpendicular to the floor, make a circular motion clockwise and counterclockwise slowly. Repeat for ten times.

Exercise 15Flex on the front wall—to prevent the deficit of the scapula	Standing in front of the wall, put the hands against the wall parallel. Flex the arms. Repeat for ten times.

Exercise	Description

Exercise 13Bar	Sitting or standing, hold the bar (about 110 cm long). Bring the arms forward and upward at the elbows extended. Flex elbows and bring the bar behind the head. Return slowly to starting position. Repeat ten times.

Exercise 14Codman's pendulum	Lying on a bed in a prone position, the arm perpendicular to the floor, make a circular motion clockwise and counterclockwise slowly. Repeat for ten times.

Exercise 15Flex on the front wall—to prevent the deficit of the scapula	Standing in front of the wall, put the hands against the wall parallel. Flex the arms. Repeat for ten times.


Plantation collaboration	I	II	III	IV	V	VI	VII

IRS/ITN re/treatment	PL in negotiation to cover; currently covered by MCP	PL in negotiation to cover; currently covered by MCP	PL in negotiation to cover; currently covered by MCP	PL subcontracts out; MCP supervises activities	PL conducts, MCP supervises activities	PL subcontracts out; MCP supervises activities	MCP covers

ITN distribution	PL in negotiation; currently covered by MCP during outbreaks	50% of workers currently covered by PL, MCP covers during outbreaks	MCP covers during outbreaks	MCP covers during outbreaks	PL covers workers; MCP may add during outbreaks	PL distributes on ad-hoc basis; MCP covers during outbreaks	MCP covers during outbreaks


Variables	IHM

Model 1	Model 2

OR	95% CI	OR	95% CI

Age	1.07	0.995–1.14	1.07	0.995–1.16


Characteristics	Median (Range)

Age, years	70 (55-85)

PSA, ng/ml	24.2 (2.6-269.6)

Hemoglobin, g/l	124 (69-156)

ALP, U/l	111 (47-2779)

LDH, U/l	208 (114-2467)

ALB, g/l	44.5 (32.3-52.2)

ECOG performance status, No. (%)

0-1	63 (90.0)

≥2	7 (10.0)

Gleason score of primary lesion, No. (%)

5-7	30 (42.9)

8-10	40 (57.1)

Site of metastatic disease1, No. (%)

Bone	65 (92.9)

Lymph node	24 (34.3)

Liver	5 (7.1)

Lung	4 (5.7)

Other soft tissue	5 (7.1)

Characteristics	Median (Range)

	)

Lung	4 (5.7)

Other soft tissue	5 (7.1)


Primer set	Primer 1	Primer 2	FAMTM Labelled Probe	VicTM Labelled Probe	Fluorescent Quencher	Anneal (1 minute)

TGFB1 -800G>A	gctatcgcctgcacacagc	aggacagaagcggtcccat	tgcctccaacgtcaccaccatc	tctgcctccaacatcaccaccatc	TAMRA	62°C

TGFB1 -509C>T	ttagccacatgggaggtgct	ccaggcggagaaggcttaa	acccttccatccctcaggtgtcct	ccctcccatccttcaggtgtcctg	TAMRA	62°C

TGFB1 +869T>C	caccacaccagccctgttc	ccaggcgtcagcaccagta	agcagcggcagca	cagcagcagcagc	None	60°C

TGFB1 +915G>C	Developed by Applied Biosystems (USA) as a Research and Development Kit	None	56°C


Inclusion criteria	Exclusion criteria

At least 16 years old	Present fracture or other joint pathology/bone matrix pathology

Visited the ER within one week after a lateral ankle sprain	A diagnosed OCD after primary inclusion

Agreed with being approached for this study	Medial ankle instability

Reported anterolateral ankle pain after an ankle sprain or ankle distortion	Previous ankle surgery

Filled out the baseline, 3-, or 6 month questionnaire; and the 12 month follow-up	An unreliable radiograph due to the angle in which it is made or low quality

	Acute surgical repair or the ATFL/CFL or any other form of surgery within 12 months after the ER visit

Inclusion criteria

At least 16 years old

Visited the ER within one week after a lateral ankle sprain

Agreed with being approached for this study

Reported anterolateral ankle pain after an ankle sprain or ankle distortion

Filled out the baseline, 3-, or 6 month questionnaire; and the 12 month follow-up

Exclusion criteria

Present fracture or other joint pathology/bone matrix pathology

A diagnosed OCD after primary inclusion

Medial ankle instability

Previous ankle surgery

An unreliable radiograph due to the angle in which it is made or low quality

Acute surgical repair or the ATFL/CFL or any other form of surgery within 12 months after the ER visit


Clinical Feature

Stage

1

2

3

4

Grade

G1

G2

G3

Residual Disease

Optimal debulking

Sub-optimal debulking

Histological type

Serous

Mucinous

Endometrioid

Clear Cell

Undifferentiated

Borderline


Types of home visits	Influencing conditions and causes	Strategies to achieve “productive performance”	Consequences of “productive performance”

• Visits on demand• Periodic visits• Nursing home round• Visits based on ad-hoc-decisions	• Nurse characteristics• Resident characteristics• Nursing home environment	Preparing strategies • Scheduling and planning • PreparingOn-site strategies • Gathering information • Seeking nurses ́ attendance • Decision making • Taking care of the residentInvesting strategies • Instructing and teaching • Dealing with documentation • Providing information	• Satisfaction• Annoyance• Disrespect• Avoiding contact to the nurses• Give up care


Criteria as provided in Figure 1	Median, days (range) No. (%)	≥0 days No. (%)	>0 days No. (%)	≤0 days No. (%)	= 0 days No. (%)	<0 days No. (%)	Ref.

Lead times

4A All histological tumor types

Criterion 1A, Rustin et	60 (0–2		13 (4	1 (			[8]


	Instrument	Baseline (T0)	2 months (T1)	4 months (T2)	8 months (T3)	12 months (T4)

Primary outcomes

Physical functioning	PCS of RAND-36	x	x	x		x

Direct and indirect costs	Tic-P	x		x	x	x

Quality of life	EQ-5D-5L	x	x	x	x	x

Secondary outcomes

HRQoL	RAND-36 subscales	x	x	x		x

Anxiety and depression	HADS	x	x	x		x

Number/severity of symptoms	PHQ-15	x	x	x		x

Potential mediators

Health anxiety	Whitely Index	x	x	x

Illness perceptions	Brief IPQ	x	x	x

Cognitions and coping	CBRQ	x	x	x

Social problem-solving skills	SPSI-R:S	x	x	x

Mastery	Pearlin Mastery Scale	x	x	x

Working alliance	WAI-SFa		x	x

	Instrument	Baseline (T0)	2 months (T1)	4 months (T2)	8 months (T3)	12 months (T4)

Potential mediators

Health anxiety	Whitely Index	x	x	x

Illness perceptions	Brief IPQ	x	x	x

Cognitions and coping	CBRQ	x	x	x

Social problem-solving skills	SPSI-R:S	x	x	x

Mastery	Pearlin Mastery Scale	x	x	x

Working alliance	WAI-SFa		x	x


Characteristic	N = 981 (%)

Demographics and Health Habits from Patient Survey

Age

 64–74 years	61

 75 + years	39

Race

 Caucasian	92

 African American	8

Gender

 Female	51

Marital status

 Never married	5

 Married	54

 Widowed	33

 Divorced/separated	9

Employed	15

Household income

 <$10,000	18

 $10,000–19,999	39

 $20,000–39,999	29

≥$40,000	14

Stratum

 Rural	30

 Suburban	45

 Veterans Affairs	20

 Inner city	5

Smoking status

 Smoker	11

 Quitter	50

 Never smoker	39

Characteristics of Visits to Primary Care Office from Medical Records

Visits/year to primary care officea (n)

 < 2	35

 2 – 3	26

 3 – 4	26

 ≥5	13

Visits to identified primary care providerb

 0 – 25%	8

 26 – 50%	12

 51 – 75%	19

 76 – 100%	62

Preventive Health Service Usage from Medical Records

Annual influenza vaccine (up to 4 seasons)	17

Pneumococcal polysaccharide vaccine	64

Tetanus toxoid	33

Mammogram among women (n = 500)

 None	11

 <1 year	59

 ≥1 year	30


References	Number of cases	Sex	Age (years)	Sites of lesion	Procedure	Recurrence

Verma and Paul [15]	1	F	39	Metacarpal	En bloc resection, autograft	No

Gebert et al. [16]	1	F	17	Radius	En bloc resection, autograft	No

Koskinen [17]	12	N/A	Adult	Limb long bones	En bloc resection, allograft	No

Traibi et al. [20]	7	6 M, 1 F	17-40	Ribs	Rib resection	No

Furukawa et al. [21]	1	F	27	Rib	Rib resection	No

Ayadi-Kaddour et al. [22]	10	5 M, 5 F	27-52	Rib	Rib resection	No

Current report	2	M	2.5, 6	Ulna, fibula	En bloc resection and autograft	Yes


Setup	AIC score	BIC score	HQC score	Prob. score

1000 individuals

1 mutation	0.07	0.0705 ± 		0.068 ± 0.


DNA Concentration	n

0 ng/μL	3

5 ng/μL	3

20 ng/μL	3

50 ng/μL	3


Age Range	Number	Percentage (%)

1-10	9	42.9


Authors (year of publication)	Population studied with CD	Prevalence of thyroid dysfunction

Collin et al. (1994) [19]	355	AITD* (19) 5.4%

	Autoimmune hypothyroidism (11) 3.1%

	Graves' disease (7) 2%

Counsell et al. (1994) [20]	107	Hyperthyroid (4) 3.7%

	Hypothyroid (11) 10.3%

Velluzzi et al. (1998) [7]	47	Hypothyroid (2) 4.3%

	 Subclinical hypothyroid (3) 6.4%

Sategna-Guidetti et al. (2001) [9]	241	Hypothyroid (31) 12.9%

	Hyperthyroid (3) 1.2%

	Euthyroid AITD (39) 16.2%

Hakanen et al. (2001) [8]	79	AITD (11)13.9%

	Graves' disease (3) 3.8%

	Hypothyroid (8) 10.1%

	Subclinical thyroid disease (8) 10.1%

Carta et al. (2002) [21]	39	Subclinical hypothyroid (3) 7.7%

Hadithi et al. (2007) [5]	184	Euthyroid (10) 5%

	Overt hypothyroidism (22) 12%

	Subclinical hypothyroid (7) 3.8%

Authors (year of publication)	Population studied with CD	Prevalence of thyroid dysfunction

Velluzzi et al. (1998) [7]	47	Hypothyroid (2) 4.3%

	Subclinical hypothyroid (3) 6.4%

Sategna-Guidetti et al. (2001) [9]	241	Hypothyroid (31) 12.9%

	Hyperthyroid (3) 1.2%

	Euthyroid AITD (39) 16.2%

Hakanen et al. (2001) [8]	79	AITD (11)13.9%

	Graves' disease (3) 3.8%

	Hypothyroid (8) 10.1%

	Subclinical thyroid disease (8) 10.1%

Carta et al. (2002) [21]	39	Subclinical hypothyroid (3) 7.7%

Hadithi et al. (2007) [5]	184	Euthyroid (10) 5%

	Overt hypothyroidism (22) 12%

	Subclinical hypothyroid (7) 3.8%


	SCQ total	SRS raw score

Factors	B	p	95%	B	p	95%

el’s p value	0.0008	.010


Site	Characteristic	Category	Unadjusted OR (95% CI)

Nouna	Malaria treatment in past 14 days	Yes vs no	0.323 (0.215, 0.484)

Other medication in the past 14 days	Yes vs no	0.563 (0.403, 0.788)

Use of insecticide sprays over 7 days	Yes vs missing/no	0.456 (0.225, 0.924)

Age	Continuous	1.159 (1.086, 1.236)

Localization	Rural vs urban area	2.635 (1.876, 3.701)

Type of location	Town vs countryside	0.386 (0.275, 0.542)

Main house construction material: floor	Natural vs cement	1.666 (1.191, 2.329)

Main source of drinking water	Open vs closed	0.712 (0.510, 0.993)

Presence of electricity	Yes vs no	0.401 (0.274, 0.588)

Saponé	Malaria treatment in past 14 days	Yes vs no	0.143 (0.066, 0.308)

Other medication in the past 14 days	Yes vs no	0.300 (0.171, 0.529)

Age	Continuous	1.329 (1.242, 1.423)

Main house construction material: roof	Iron sheet vs grass/palm	0.631 (0.440, 0.906)

Site	Characteristic	Category	Unadjusted OR (95% CI)

Nouna	Age	Continuous	1.159 (1.086, 1.236)

Localization	Rural vs urban area	2.635 (1.876, 3.701)

Type of location	Town vs countryside	0.386 (0.275, 0.542)

Main house construction material: floor	Natural vs cement	1.666 (1.191, 2.329)

Main source of drinking water	Open vs closed	0.712 (0.510, 0.993)

Presence of electricity	Yes vs no	0.401 (0.274, 0.588)

Saponé	Malaria treatment in past 14 days	Yes vs no	0.143 (0.066, 0.308)

Other medication in the past 14 days	Yes vs no	0.300 (0.171, 0.529)

Age	Continuous	1.329 (1.242, 1.423)

Main house construction material: roof	Iron sheet vs grass/palm	0.631 (0.440, 0.906)


Allele	Slope	Efficiency (%)	R2	y-intercepts

Wild-type-sensitive	3.39	97.2	0.998	37.705

Mutant-resistant	2.59	142.7	0.991	36.531

Allele	Slope	Efficiency (%)	R2	y-intercepts

Wild-type-	3.3	97.	0.998	37


	cTAKES [4]	NOBLE Coder [20]	MetaMap [31, 32]	NCBO annotator [14]

Modularity/configuration options	Modular text processing pipeline	Vocabulary (terminology);Term matching options and strategies	Text processing pipeline;Vocabulary (terminology);Term matching options and strategies	Vocabulary (terminology);Term matching options

Disambiguation of terms	Enabled through integration of the YTEX component [8]	Instead of through WSD, it uses heuristics to choose one concept among candidate concepts for the same piece of input text	Supported; based on:- removal of word senses based on a manual study of UMLS ambiguity- a WSD algorithm that chooses a concept with the most likely semantic type for a given context	Not supported

Vocabulary (terminology)	Subset of UMLS, namely SNOMED CT and RxNORM	Several pre-built vocabularies, based on subsets of UMLS(e.g. SNOMED CT, MeSH, RxNORM)	UMLS Metathesaurus	UMLS Metathesaurus and BioPortal ontologies (over 330 ontologies)

Speed*	Suitable for real-time processing 	Suitable for real-time processing	Better for off-line batch processing	Suitable for real-time processing

Implementation form	Software (Java) library;Stand-alone application	Software (Java) library;Stand-alone application	Software library;originally version in Prolog;Java implementation, known as MMTX, is also available	RESTful Web service

Availability	open source;available under Apache License, v.2.0	open-source;available under GNU Lesser General Public License v3	open source;terms and conditions at: https://metamap.nlm.nih.gov/MMTnCs.shtml	closed source, but freely available

Specific features	Better performance on clinical texts than on biomedical scientific literature (its NLP components are trained on clinical texts)	Offers user interface for creating custom terminologies (to be used for annotation) by selecting and merging elements from several different thesauri/ontologies	Primarily developed for annotation of biomedical literature (MEDLINE/PubMed citations); performs better on this kind of text than clinical notes	It uses MGrep term-to-concept matching tool to get primary set of annotations; these are then extended using different forms of ontology-based semantic matching

URL	http://ctakes.apache.org/	http://noble-tools.dbmi.pitt.edu/	https://metamap.nlm.nih.gov/	https://bioportal.bioontology.org/annotator

	cTAKES [4]	NOBLE Coder [20]	MetaMap [31, 32]	NCBO annotator [14]

Modularity/configuration options	Modular text processing pipeline	Vocabulary (terminology);Term matching options and strategies	Text processing pipeline;Vocabulary (terminology);Term matching options and strategies	Vocabulary (terminology);Term matching options

Disambiguation of terms	Enabled through integration of the YTEX component [8]	Instead of through WSD, it uses heuristics to choose one concept among candidate concepts for the same piece of input text	Supported; based on:- removal of word senses based on a manual study of UMLS ambiguity- a WSD algorithm that chooses a concept with the most likely semantic type for a given context	Not supported

Vocabulary 	Subset of UM	Several pre-built vocabularie	UMLS Met	UMLS Metathesaurus and BioPortal ontologi

(terminology)	LS, namely SNOMED CT and RxNORM	s, based on subsets of UMLS(e.g. SNOMED CT, MeSH, RxNORM)	athesaurus	es (over 330 ontologies)

Speed*	Suitable for real-time processing	Suitable for real-time processing	Better for off-line batch processing	Suitable for real-time processing

Implementation form	Software (Java) library;Stand-alone application	Software (Java) library;Stand-alone application	Software library;originally version in Prolog;Java implementation, known as MMTX, is also available	RESTful Web service

Availability	open source;available under Apache License, v.2.0	open-source;available under GNU Lesser General Public License v3	open source;terms and conditions at: https://metamap.nlm.nih.gov/MMTnCs.shtml	closed source, but freely available

Specific features	Better performance on clinical texts than on biomedical scientific literature (its NLP components are trained on clinical texts)	Offers user interface for creating custom terminologies (to be used for annotation) by selecting and merging elements from several different thesauri/ontologies	Primarily developed for annotation of biomedical literature (MEDLINE/PubMed citations); performs better on this kind of text than clinical notes	It uses MGrep term-to-concept matching tool to get primary set of annotations; these are then extended using different forms of ontology-based semantic matching

URL	http://ctakes.apache.org/	http://noble-tools.dbmi.pitt.edu/	https://metamap.nlm.nih.gov/	https://bioportal.bioontology.org/annotator


Eukaryotic organisms	%	Prokaryotic organisms	%

Chloromonas pseudoplatyrhyncha	26.93	Rhodoferax sp.	21.94

Stephanodiscus sp.	18.17	Unsequenced organisms	17.84

Unsequenced organisms	17.87	Flavobacterium sp.	9.43

Chromulinaceae sp.	8.48	Anabaena sp.	8.85

Synedra angustissima	4.99	Brevundimonas diminuta	4.20

Ochromonadales sp.	3.01	Hydrogenophaga sp.	3.41

Chlamydomonas sp.	2.98	Runella limosa	2.47

Micractinium pusillum	1.62	Haliscomenobacter sp.	2.43

Chlorella sp.	1.08	Rhodobacter sp.	2.34

Pythiaceae sp.	1.07	Planktophila limnetica	2.13

		Agrobacterium tumefaciens	2.11

		Sphingobacterium sp.	2.03

		Ochrobactrum tritici	1.98

		Brevundimonas variabilis	1.83

		Sphingomonas sp.	1.73

		Curvibacter sp.	1.48

		Phenylobacterium falsum	1.42

		Roseomonas stagni	1.24

		Oceanicaulis sp.	1.03


	Hazard ratio	P value	Standard Error	95% CI

Age

<40	Reference

[40, 6	1	0.10	0.835	0.8623	4.5


Variable	Disease-Free Survival	Progression-Free Survival

OverallPopulation67 pts	BCG	No BCG	OverallPopulation63 pts	BCG	No BCG


	Adjusted HRa	(95 % CI)

Without antipsychotics	1.40	(1.18, 1.66)

With antipsychotics	1.45	(1.16, 1.82)

Without anticoagulant	1.44	(1.25, 1.65)

With anticoagulant	1.24	(0.76, 2.00)

Without antiplatelet	1.41	(1.23, 1.62)

With antiplatelet	1.52	(0.72, 3.22)

Without anti-inflammatory	1.29	(0.90, 1.85)

With anti-inflammatory	1.44	(1.24, 1.67)

Without anxiety or other mood disorders	1.40	(1.07, 1.82)

With anxiety or other mood disorders	1.42	(1.21, 1.66)

Without atrial fibrillation	1.40	(1.22, 1.62)

With atrial fibrillation	1.57	(0.98, 2.50)

Without coronary heart disease	1.36	(1.16, 1.60)

With coronary heart disease	1.59	(1.24, 2.05)

Without congestive heart failure	1.44	(1.25, 1.65)

With congestive heart failure	1.15	(0.68, 1.97)

Without chronic obstructive pulmonary disease	1.49	(1.29, 1.73)

With chronic obstructive pulmonary disease	1.09	(0.77, 1.54)

Without cancer	1.42	(1.24, 1.63)

With cancer	0.94	(0.26, 3.32)

Without diabetes mellitus	1.20	(0.99, 1.45)

With diabetes mellitus+	1.70	(1.41, 2.05)

Without hypertension	1.25	(0.69, 2.27)

With hypertension	1.42	(1.24, 1.64)

Without hyperlipidemia	1.41	(1.18, 1.68)

With hyperlipidemia	1.42	(1.15, 1.76)

Antidepressants use before index date

 No--New Users	1.57	(1.32, 1.86)

 Yes--Prevalent Users	1.23	(0.99, 1.53)

Depression at Baseline (index date) or Post-stroke

 No Depression	1.55	(1.32, 1.82)

 Depression at Baseline	1.49	(0.99, 2.26)

 Post-stroke Depression	1.44	(1.01, 2.07)

	Adjusted HRa	(95 % CI)

Without antipsychotics	1.40	(1.18, 1.66)

With antipsychotics	1.45	(1.16, 1.82)

Without anticoagulant	1.44	(1.25, 1.65)

Wit	1.2	(0.76, 2.00

h anticoagulant	4	)

Without antiplatelet	1.41	(1.23, 1.62)

With antiplatelet	1.52	(0.72, 3.22)

Without anti-inflammatory	1.29	(0.90, 1.85)

With anti-inflammatory	1.44	(1.24, 1.67)

Without anxiety or other mood disorders	1.40	(1.07, 1.82)

With anxiety or other mood disorders	1.42	(1.21, 1.66)

Without atrial fibrillation	1.40	(1.22, 1.62)

With atrial fibrillation	1.57	(0.98, 2.50)

Without coronary heart disease	1.36	(1.16, 1.60)

With coronary heart disease	1.59	(1.24, 2.05)

Without congestive heart failure	1.44	(1.25, 1.65)

With congestive heart failure	1.15	(0.68, 1.97)

Without chronic obstructive pulmonary disease	1.49	(1.29, 1.73)

With chronic obstructive pulmonary disease	1.09	(0.77, 1.54)

Without cancer	1.42	(1.24, 1.63)

With cancer	0.94	(0.26, 3.32)

Without diabetes mellitus	1.20	(0.99, 1.45)

With diabetes mellitus+	1.70	(1.41, 2.05)

Without hypertension	1.25	(0.69, 2.27)

With hypertension	1.42	(1.24, 1.64)

Without hyperlipidemia	1.41	(1.18, 1.68)

With hyperlipidemia	1.42	(1.15, 1.76)

Antidepressants use before index date

No--New Users	1.57	(1.32, 1.86)

Yes--Prevalent Users	1.23	(0.99, 1.53)

Depression at Baseline (index date) or Post-stroke

No Depression	1.55	(1.32, 1.82)

Depression at Baseline	1.49	(0.99, 2.26)

Post-stroke Depression	1.44	(1.01, 2.07)


Brain regions	Peak MNI, mm	T score

	X	Y	Z

MHE vs. Controls (FDR corrected, p < 0.05)

Right fusiform gyrus	24	0	−49	5.11

Right rectus	6	51	−21	4.25

Right thalamus	21	−26	0	−5.83

Right superior frontal gyrus	15	−3	75	4.43

Left paracentral lobule	−15	−36	75	4.49

Right postcentral gyrus	12	−45	78	4.59

Right calcarine	3	−69	15	−3.77

NMHE vs. Controls (FDR corrected, p < 0.05)

Right frontal pole	6	54	−27	4.22

Right superior frontal gyrus	12	−12	78	4.51

Right thalamus	18	−27	0	−4.15

Right calcarine	6	−69	18	−4.84

Left precentral gyrus	−27	−21	72	5.18

Left middle frontal gyrus	−42	30	45	5.60

MHE vs. NMHE (uncorrected, p < 0.001)

Right postcentral gyrus	18	−39	75	3.53


Trial	MEK Inhibitor	PI3K Inhibitor	Phase	Population

NCT01363232	MEK162	BKM120	Phase I	Patients with advanced solid cancers (colorectal cancer, triple-negative breast cancer, pancreatic cancer, and other cancers harboring KRAS, BRAF and NRAS mutations)

NCT01392521	BAY86-9766	BAY80-6946	Phase Ib	Patients with advanced solid cancers

NCT01449058	MEK162	BYL719	Phase II	Patients with advanced solid cancers (colorectal cancer, esophageal cancer, pancreatic cancer, non-small cell lung cancer, and other advanced solid tumors harboring RAS or BRAF mutations)

Trial	MEK Inhibitor	PI3K/mTOR Inhibitor	Phase	Population

NCT00996892	GDC-0973	Pictilisb (GDC-0941)	Phase I	Patients with advanced solid cancers

NCT01337765	MEK162	BEZ235	Phase 1	Patients with advanced solid cancers (colorectal cancer, triple-negative breast cancer, pancreatic cancer, malignant melanoma, non-small cell lung cancer, and other cancers harboring KRAS, BRAF and NRAS mutation)

NCT01390818	Pimasertib (MSC1936369B)	SAR245409	Phase 1	Patients with advanced solid cancers (colorectal cancer, pancreatic cancer, thyroid cancer, non-small cell lung cancer, renal cancer, breast cancer, melanoma, ovarian cancer) and any cancer diagnosed with aberrations in one or more the following genes: PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2)

NCT01347866	PD0325901	PF-05212384	Phase 1	Patients with advanced solid cancers harboring KRAS or BRAF mutation and patients with KRAS mutation with no more than one prior systemic therapy regimen

Trial	MEK Inhibitor	AKT Inhibitor	Phase	Population

NCT01562275	GDC-0973	GDC-0068	Phase 1	Patients with locally advanced or metastatic solid tumors


	Day 3	Day 5

Chemicals	ET	TO	CP	CP + PM	ET	TO	CP	CP + PM


Checklist item	Condition	Session observed	Outcome

Timing from first slide to class exercise	Contact	First module	10–12 min

Education	Second module	10–26 min

Time allocated to first exercise	Contact	First module	8–13 min

Education	Second module	5–10 min

Are any slides skipped?	Contact	First module	No, in all observed classes.

Education	Second module	No, in all observed classes.

Are pupils asked if they have questions?	Contact	First module	Yes, in all observed classes.

Education	Second module	Yes, in all observed classes.

Are the majority of students engaging in class?	Contact	First module	Yes, in all observed classes.

Education	Second module	Yes, in all observed classes.

Size of group for first exercise	Contact	First module	2–7

Education	Second module	3–5

Does a facilitator visit each group during exercise?	Contact	First module	Yes, in all observed classes.

Education	Second module	Yes, in all observed classes.

Do all groups manage to finish exercise in allocated time?	Contact	First module	Yes in 4 observed classes, no in 2 observed classes.

Education	Second module	Yes, in all observed classes.


Perceived stress variables	Factor loading

Factor 1	Factor 2	Factor 3

Pressure and demands	Eigenvalue 5.97 Cronbach’s alpha 0.83

I don’t have enough time	0.754

I feel under pressure from school demands	0.698

I feel helpless	0.671

I never feel really free	0.641

I feel under pressure from demands at home	0.563

I feel under pressure from my inner demands	0.536

I don’t feel rested after sleep	0.531

Activation/high tempo	 	Eigenvalue 1.41 Cronbach’s alpha 0.72

I rush even if I don’t have to	 	0.721

I keep a high speed all the day	 	0.700

I eat rapidly even if I don’t have to	 	0.576

I do many things at the same time	 	0.551

I find it difficult to relax	 	0.533

Sleep problems	 	 	Eigenvalue 1.04 Cronbach’s alpha 0.82

I sleep restlessly and shallow	 	 	0.763

I have difficulty falling asleep	 	 	0.739

I wake up early in the morning	 	 	0.606

I feel restless	 	 	0.524

Perceived stress variables

Pressure and demands

I don’t have enough time

I feel under pressure from school demands

I feel helpless

I never feel really free

I feel under pressure from demands at home

I feel under pressure from my inner demands

I don’t feel rested after sleep

Activation/high tempo

I rush even if I don’t have to

I keep a high speed all the day

I eat rapidly even if I don’t have to

I do many things at the same time

I find it difficult to relax

Sleep problems

I sleep restlessly and shallow

I have difficulty falling asleep

I wake up early in the morning

I feel restless


	QubitTM	Spike-in QubitTM

Kit	Sample vol. (μL)	Reading (pg/μL)	[RNA] (pg/μL)	Sample Vol. (μL)	Reading ± SD (pg/μL)	[RNA] ± SD (pg/μL)	CV


Risk factor

Curve progression	Female genderLarge curve magnitudeSkeletal immaturity

Female body type	Much thinnerDecreased body weightDecreased chest girthDecreased body mass index

Risk factor

Curve	Female genderLarge curve magnitudeSkele

 progression	tal immaturity

Female body type	Much thinnerDecreased body weightDecreased chest girthDecreased body mass index


No of patients with antibodies against:	IL-10	IL-10R1	IL-10R2	IL-10 + IL-10R1	IL-10 + IL-10R2	IL-10 + IL-10R1 + IL-10R2

IgG	3	2	1	1	2	1

IgA	2	-	-	11	-	-

Total noof patients	5	2	1	2	2	1


Characteristics	Frequency	Percentage

Ever donated blood	126	29.9

Frequency of donation in lifetime (N = 126)

 Once	57	45.2

 Repeated	69	54.8

Donated in the past 5 years	124	98.4

Donated in the past 12 months	123	97.6

Types of donation

 Voluntary	114	90.5

 Paid	2	1.6

 Replacement	10	7.9

Main reason(s) for the last time donation

 Voluntarism	114	90.5

 HIV results	2	1.6

 Replacement	10	7.9

Would you donate blood again in the future?

 Yes	120	95.2

 No	6	4.8

The place of your last donation

 Blood Transfusion Centre	15	12

 Hospital	28	22.4

 School	82	65.6

Experienced negative effect after donation

 Yes	39	31

 No	87	69

Postdonation negative effect (N = 39)

 Pain	1	1

 Dizziness	37	94.9

 Fever	1	2.6


Severity criteria	Score

Smoking status

 Never-smoker	0

 Smoker	1

Symptoms

 No	0

 Yes	1

PaO2, mmHg

 ≥80	0

 60–80	1

 <60	2

HRCT score

 ≤8	1

 8–16 	2

 16–24	3

 24–32	4

DLCO, % predicted

 ≥80	0

 60–80	1

 <60	2

Severity criteria	Score

8–16	2

16–24	3

24–32	4

DLCO, % predicted

≥80	0

60–80	1

<60	2


	Body weight (grams)	Cholesterol (mg/dL)

C57BL/6	30 ± 1	91 ± 5

AS (15 weeks)	31 ± 2	749 ± 148

AS (30–35 weeks)	28 ± 1	596 ± 52

AS + apocynin (34–35 weeks)	28 ± 1	592 ± 155


	Mantel r	Mantel P	K* P	Maddison and Slatkin P	Data type	Trait group

All traits	0.63	0.001	–	–	Multiple traits	Group of traits

α niche traits	0.38	0.001	–	–	Multiple traits	Group of traits

β niche traits	0.17	0.005	–	–	Multiple traits	Group of traits

Voltinism	0.25	0.001	0.001	–	Ordinal	Life cycle

Adult life span	0.40	0.001	–	0.001	Nominal	Life cycle

Exoskeleton	0.27	0.001	–	0.001	Nominal	Morphology/physiology

Body shape	0.26	0.001	–	0.001	Nominal	Morphology/physiology

Respiration	0.09	0.060	–	0.001	Nominal	Morphology/physiology

BMWP	0.14	0.001	0.001	–	Quantitative	Morphology/physiology

Body size	0.27	0.001	0.001	–	Ordinal	Morphology/physiology

Flight capacity	0.21	0.001	0.001	–	Ordinal	Morphology/physiology

Shelter	0.05	0.110	–	0.001	Nominal	Behavioral

Reophily	0.09	0.034	–	0.199	Nominal	Behavioral

Micro habitat	0.27	0.001	–	0.001	Nominal	Behavioral

Trophic position	0.20	0.001	–	0.001	Nominal	Behavioral


Number of collected ovaries	Number of cultured COCs	Number of mature oocytes	Number of Cas9/sgRNA injection oocytes	Cleavage rate at 48 hr post activation	Blastocyst development rate at 144 hr post activation

Injected group	Untreated group	Injected group	Untreated group	Injected group	Untreated group

400	810	420	195	225	52.8% (103/195)a	40.4% (91/225)b	14.4% (28/195)a	13.3% (30/225)a

Number of collected ovaries	Number of cultured COCs	Number of mature oocytes

400	810	420

Number of Cas9/sgRNA injection oocytes	Cleavage rate at 48 hr post activation	Blastocyst development rate at 144 hr post activation

Injected group	Untreated group	Injected group	Untreated group	Injected group	Untreated group

195	225	52.8% (103/195)a	40.4% (91/225)b	14.4% (28/195)a	13.3% (30/225)a


Type of abuse	Abusive incidents (n=209)*

N	%

Minor incidents	208	99.9%

Major incidents	55	26.0%

Severe incidents	17	8.0%

Type of abuse	Abusive incidents (n=209)*

N

Minor incidents	208

Major incidents	55

Severe incidents	17


 Trial	Regiments	N	CR	OR	OS (months)	Median PFS (months)

Robak et al. [25]	RC	18	13%	67%	ND	12

versus RCC	28	9%	78%	ND	12

Robak et al. [26]	FC	276	13%	58%	46	20.6

versus RFC	276	24.3%	69.6%	64	30.6

 Castro et al. [27]	Rituximab HDMP	14	36%	93%	ND	ND

Wierda [28]	Ofatumumab, FA-ref,	95	0%	51%	14.2	5.5

versus ofatumumab, BF-ref	111	2%	54%	17.4	5.5

 Gritti et al. [29]	Alemtuzumab	18	8%	44%	ND	14.6

 Zent et al. [30]	PAR	19	32%	74%	23	7

 Badoux et al. [31]	CFAR	31	29%	65%	11	7

O'Brien et al. [32]	FC	120	9%	17%	34	6

versus FC-oblimersen	121	3%	7%	33	9

 Chen et al. [33]	Lenalidomide	25	0%	56%	24	24


AFB1 Spiked Level (μg/kg)	AFB1 Recovery * (μg/kg)	R (%)

Assay 1	Assay 2	Assay 3	Assay 4	Assay 5	Mean ± SD

5.	4	4.64	4.3	4.5	4.	4.54 ±	90


Species	Suckling Duration (s)	Reference

Southern right whales	90–210	Thomas & Taber 1984 [35]

Bowhead whale	<60 	Wursig et al., 1984 [36]

Gray whale	20–76 	Smultea et al., 2017 [34]

Blue whale	13–264 	Smultea et al., 2017 [34]

Fin whale	30–138 	Smultea et al., 2017 [34]


Respondent nr.	Deceased patient	Family caregiver (Respondent)

	Sex	Age	Diagnosis	Relation to patient	Sex	Age	Terminal leave	Occupation status

1	Male	72	Lung cancer	Spouse	Female	63	No	On pension

2	Male	72	Lung cancer	Spouse	Female	70	No	On pension

3	Male	63	Primary tumour unknown	Spouse	Female	55	Yes	Active work

4	Female	56	Pancoast tumour (lung cancer)	Spouse	Male	59	No	Unemployed

5	Female	63	Lung cancer	Spouse	Male	69	No	On pension

6	Male	57	Lung cancer	Spouse	Female	56	Yes	Active work

7	Female	53	Breast cancer	Spouse	Male	56	Yes	Active work


Characteristic	n (%)a

Maternal age (years)

< 27	13,614	(20.6)

27–29	17,880	(27.0)

30–32	16,517	(25.0)

> 32	18,192	(27.5)

Parity

Primiparous	29,574	(44.7)

Multiparous	34,240	(51.7)

Unknown	2,389	(3.6)

General maternal health

Very good	33,454	(50.5)

Average	28,114	(42.5)

Bad	2,263	(3.4)

Unknown	2,372	(3.6)

Socioeconomic status

High	32,627	(49.3)

Medium	23,299	(35.2)

Low	5,220	(7.9)

Unknown	5,057	(7.6)

Infant sex

Male	33,779	(51.0)

Female	32,424	(49.0)

Hypertension during pregnancy

Yes	8,824	(13.3)

No	57,192	(86.4)

Unknown	187	(0.3)

Gestational diabetes

Yes	1,632	(2.5)

No	64,225	(97.0)

Unknown	346	(0.5)

Smoking

Yes	17,020	(25.7)

No	47,255	(71.4)

Unknown	1,928	(2.9)

Maternal life stress during pregnancyb (score)

Low (0)	19,793	(29.9)

Low-medium (> 0 to ≤ 1)	14,488	(21.9)

Medium-high (> 1 to ≤ 3)	20,377	(30.8)

High (> 3)	11,545	(17.4)

Maternal emotional stress during pregnancyb (score)

Low (≤ 1)	25,083	(37.9)

Low-medium (> 1 to ≤ 2)	11,432	(17.3)

Medium-high (> 2 to ≤ 4)	15,971	(24.1)

High (> 4)	13,717	(20.7)

Maternal life stress after pregnancyb (score)

Low (0)	32,296	(48.8)

Low-medium (> 0 to ≤ 1)	13,829	(20.9)

Medium-high (> 1 to ≤ 2)	9,725	(14.7)

High (> 2)	10,353	(15.6)

Maternal emotional stress after pregnancyb (score)

Low (0)	22,313	(33.7)

Low-medium (> 0 to ≤ 1)	12,557	(19.0)

Medium-high (> 1 to ≤ 3)	15,847	(23.9)

High (> 3)	15,486	(23.4)

aPercentages may not total 100 because of rounding. bStress groups were defined by the closest possible cutoffs to the quartiles of their distribution.

Characteristic

Maternal age (years)

< 27

27–29

30–32

> 32

Parity

Primiparous

Multiparous

Unknown

General maternal health

Very good

Average

Bad

Unknown

Socioeconomic status

High

Medium

Low

Unknown

Infant sex

Male

Female

Hypertension during pregnancy

Yes

No

Unknown

Gestational diabetes

Yes

No

Unknown

Smoking

Yes

No

Unknown

Maternal life stress during pregnancyb (score)

Low (0)

Low-medium (> 0 to ≤ 1)

Medium-high (> 1 to ≤ 3)

High (> 3)

Maternal emotional stress during pregnancyb (score)

Low (≤ 1)

Low-medium (> 1 to ≤ 2)

Medium-high (> 2 to ≤ 4)

High (> 4)

Maternal life stress after pregnancyb (score)

Low (0)

Low-medium (> 0 to ≤ 1)

Medium-high (> 1 to ≤ 2)

High (> 2)

Maternal emotional stress after pregnancyb (score)

Low (0)

Low-medium (> 0 to ≤ 1)

Medium-high (> 1 to ≤ 3)

High (> 3)

aPercentages may not total 100 because of rounding. bStress groups were defined by the closest possible cutoffs to the quartiles of their distribution.


Model	Aquatic species

AEV

Month	67.3%

Humidity (H)	16.0%

Temperature (T)	23.1%

Wind speed (W)	7.6%

Cloud cover (C)	3.1%

Air pressure	0.9%

T + TH regime	35.8%

T + H	35.7%

H + TH regime	33.2%

T + H + Wa	38.8%

T + H + W (month)	0%

H + W + Cb	–

H + W + C (month)	–


 	Odds ratio	95% CI	p*

Presence of psychotic symptoms

Switch	0.34	0.08 to 1.48	0.152

Augmentation	3.25	1.02 to 10.31	0.045

Number of major depressive episodes

Switch	0.96	0.83 to 1.11	0.558

Augmentation	1.23	1.07 to 1.43	0.005


Motion	Reconstructed ankle	Normal ankle

Dorsiflexion	24.2° ± 5.84°	24.7° ± 4.85°*

Plantarflexion	43.7° ± 5.74°	43.4° ± 4.10°*

Motion	Reconstructed ankle	Normal ankle

Plantarflexion	43.7° ± 5.74°	43.4° ± 4.10°*


Target	Sequences

IL-18	Forward 5'-GAAACGTCAATAGCCAGTTGC-3'

	Reverse 5'-TCCCATGCTCTTTCTCACAACA-3'

IL-10	Forward 5'-AGCAGATCAAGGAGACGTTC-3'

	Reverse 5'-ATCAGCAGGTACTCCTCGAT-3'

IL-8	Forward 5’-TATCACTGGAGAGTCTCGCTGTC-3’

	Reverse 5’-TCAGTCCTCCTGCAGTGTATACC-3’

IFN-γ	Forward 5' - ACACTGACAAGTAAAGCCGCACA-3'

	Reverse 5' -AGTCGTTCATCGGGAGCTTGGC-3'

β-actin	Forward 5'-CAACACAGTGCTGTCTGGTGGTA-3'

	Reverse 5'-ATCGTACTCCTGCTTGCTGATCC-3'

Target	Sequences

IL-18	Forward 5'-GAAACGTCAATAGCCAGTTGC-3'

	Reverse 5'-TCCCATGCTCTTTCTCACAACA-3'

IL-	Forward 5'-A

Target	Sequences

10	GCAGATCAAGGAGACGTTC-3'

	Reverse 5'-ATCAGCAGGTACTCCTCGAT-3'

IL-8	Forward 5’-TATCACTGGAGAGTCTCGCTGTC-3’

	Reverse 5’-TCAGTCCTCCTGCAGTGTATACC-3’

IFN-γ	Forward 5' - ACACTGACAAGTAAAGCCGCACA-3'

	Reverse 5' -AGTCGTTCATCGGGAGCTTGGC-3'

β-actin	Forward 5'-CAACACAGTGCTGTCTGGTGGTA-3'

	Reverse 5'-ATCGTACTCCTGCTTGCTGATCC-3'


Disease Stage	Gene Symbol	Accession Number	Fold Change (FC)

HTA 2.0	qRT-PCR

Normal vs. HCV+			CA	AA	CA	AA

	SAA1	NM_000331	3.36	NA	3.12	2.0*

	AOX1	NM_001159	3.45	NA	3.10	3.3


Characteristic	Systemic sclerosis (n = 90)	Systemic lupus erythematosus (n = 100)

Female	78 (86.7%)	87 (87%)

Age (years)	57.7 ± 14.4	48.1 ± 15.1

Disease duration (months)	85.0 ± 96.0	69.6 ± 92.0

Body mass index	24.5 ± 4.0	25.2 ± 4.7

Adipositas, body mass index >30	6 (6.7%)	14 (14%)

Hypertension	45 (50%)	56 (56%)

 Systolic blood pressure (mmHg)	129.9 ± 23.2	130.6 ± 21.5

 Diastolic blood pressure (mmHg)	75.9 ± 11.5	77.6 ± 10.6

 Mean number of antihypertensives	0.8 (0, 4)	0.9 (0, 6)

Diabetes	4 (4.4%)	6 (6%)

Pulmonary hypertension	17 (18.9%)	3 (3%)

Coronary heart disease	10 (11.1%)	9 (9%)

Peripheral artery vessel disease	5 (5.6%)	2 (2%)

Nicotine use, current or former	43 (47.8%)	53 (53%)

 Nicotine pack-years	10.7 ± 19.5	10.4 ± 16.2

Triglyceride (mg/dl)	139.2 ± 84.9	128.1 ± 69.9

Cholesterol (mg/dl)	216.5 ± 50.2	213.9 ± 59.6

Low density lipoprotein (mg/dl)	125.5 ± 39.2	123.7 ± 46.8

High density lipoprotein (mg/dl)	63.7 ± 18.7	64.4 ± 17.9

Family history of cardiovascular disease	12 (13.3%)	16 (16%)

Mean Rodnan skin score (median, range)	11 (9, 43)	–

Mean SLEDAI (median, range)	–	11 (9, 60)

Mean SLICC (median, range)	–	2 (2, 8)

Characteristic	Systemic sclerosis (n = 90)	Systemic lupus erythematosus (n = 100)

Female	78 (86.7%)	87 (87%)

Age (years)	57.7 ± 14.4	48.1 ± 15.1

Disease duration (months)	85.0 ± 96.0	69.6 ± 92.0

Body mass index	24.5 ± 4.0	25.2 ± 4.7

Adipositas, body mass index >30	6 (6.7%)	14 (14%)

Hypertension	45 (50%)	56 (56%)

Systolic blood pressure (mmHg)	129.9 ± 23.2	130.6 ± 21.5

Diastolic blood pressure (mmHg)	75.9 ± 11.5	77.6 ± 10.6

Mean number of 	0.8 (	0.9 (

antihypertensives	0, 4)	0, 6)

Diabetes	4 (4.4%)	6 (6%)

Pulmonary hypertension	17 (18.9%)	3 (3%)

Coronary heart disease	10 (11.1%)	9 (9%)

Peripheral artery vessel disease	5 (5.6%)	2 (2%)

Nicotine use, current or former	43 (47.8%)	53 (53%)

Nicotine pack-years	10.7 ± 19.5	10.4 ± 16.2

Triglyceride (mg/dl)	139.2 ± 84.9	128.1 ± 69.9

Cholesterol (mg/dl)	216.5 ± 50.2	213.9 ± 59.6

Low density lipoprotein (mg/dl)	125.5 ± 39.2	123.7 ± 46.8

High density lipoprotein (mg/dl)	63.7 ± 18.7	64.4 ± 17.9

Family history of cardiovascular disease	12 (13.3%)	16 (16%)

Mean Rodnan skin score (median, range)	11 (9, 43)	–

Mean SLEDAI (median, range)	–	11 (9, 60)

Mean SLICC (median, range)	–	2 (2, 8)


Age at profound hearing loss mean (std.) [min–max]

20.1 (18.5) [1.5–49.0]

0.5 (1.1) [0.0–3.5]


	Duloxetine	Venlafaxine	SSRI	Untreated

N removed	N eligible remaining	N removed	N eligible remaining	N removed	N eligible remaining	N removed	N eligible remaining

Member of commercial health insurance plan, with medical coverage and pharmacy benefits, and presence of qualifying eventa during the accrual period		156,682 (100.0 %)		231,793 (100 %)		1,314,147 (100 %)		1,577,784 (100 %)

Baseline exclusions

 Less than 18 years at index date	1396	155,286 (99.1 %)	2482	229,311 (98.9 %)	33,476	1,280,671 (97.5 %)	60,552	1,517,232 (96.2 %)

 Less than 12 months prior continuous enrollment	79,819	75,467 (48.2 %)	136,147	93,164 (40.2 %)	780,943	499,728 (38.0 %)	791,027	726,205 (46.0 %)

 Prior dispensing of study drug or drug class in the baseline	0	75,467 (48.2 %)	23,753	69,411 (29.9 %)	134,294	365,434 (27.8 %)	334,496	391,709 (24.8 %)

 Had no depression diagnosis in the baseline	27,596	47,871 (30.6 %)	24,844	44,567 (19.2 %)	153,173	212,261 (16.2 %)	0	391,709 (24.8 %)

 Had hepatic injury/chronic hepatic condition in the baseline	10,592	37,279 (23.8 %)	9173	35,394 (15.3 %)	39,354	172,907 (13.2 %)	76,815	314,894 (20.0 %)

 Region affected by Hurricane Katrina	489	36,790 (23.5 %)	509	34,885 (15.1 %)	2020	170,887 (13.0 %)	3556	311,338 (19.7 %)

Cohort assignment based on earliest qualifying index date (pre-propensity score matching)	30,844 (19.7 %)	29,243 (12.6 %)	166,236 (12.6 %)	311,338 (19.7 %)

	Duloxetine	Venlafaxine	SSRI	Untreated

N removed	N eligible remaining	N removed	N eligible remaining	N removed	N eligible remaining	N removed	N eligible remaining

Had no depression diagnosis in the baseline	27,596	47,871 (30.6 %)	24,844	44,567 (19.2 %)	153,173	212,261 (16.2 %)	0	391,709 (24.8 %)

Had hepatic injury/chronic hepatic condition in the baseline	10,592	37,279 (23.8 %)	9173	35,394 (15.3 %)	39,354	172,907 (13.2 %)	76,815	314,894 (20.0 %)

Region affected by Hurricane Katrina	489	36,790 (23.5 %)	509	34,885 (15.1 %)	2020	170,887 (13.0 %)	3556	311,338 (19.7 %)

Cohort assignment based on earliest qualifying index date (pre-propensity score matching)	30,844 (19.7 %)	29,243 (12.6 %)	166,236 (12.6 %)	311,338 (19.7 %)